<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2022-09-19T18:02:17Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8594602" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8594602</identifier>
        <datestamp>2021-12-07</datestamp>
        <setSpec>iai</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Infect Immun</journal-id>
              <journal-id journal-id-type="iso-abbrev">Infect Immun</journal-id>
              <journal-id journal-id-type="publisher-id">IAI</journal-id>
              <journal-title-group>
                <journal-title>Infection and Immunity</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0019-9567</issn>
              <issn pub-type="epub">1098-5522</issn>
              <publisher>
                <publisher-name>American Society for Microbiology</publisher-name>
                <publisher-loc>1752 N St., N.W., Washington, DC</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8594602</article-id>
              <article-id pub-id-type="pmcid">PMC8594602</article-id>
              <article-id pub-id-type="pmc-uid">8594602</article-id>
              <article-id pub-id-type="pmid">34516235</article-id>
              <article-id pub-id-type="pmid">34516235</article-id>
              <article-id pub-id-type="publisher-id">00346-21</article-id>
              <article-id pub-id-type="doi">10.1128/IAI.00346-21</article-id>
              <article-id pub-id-type="publisher-id">iai.00346-21</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Microbial Immunity and Vaccines</subject>
                </subj-group>
                <subj-group subj-group-type="biological-terms">
                  <compound-subject>
                    <compound-subject-part content-type="code">immunology</compound-subject-part>
                    <compound-subject-part content-type="label">Immunology</compound-subject-part>
                  </compound-subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Mucosal Immunization with DTaP Confers Protection against <italic toggle="yes">Bordetella pertussis</italic> Infection and Cough in Sprague-Dawley Rats</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hall</surname>
                    <given-names>Jesse M.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                  <xref rid="aff2" ref-type="aff">
                    <sup>b</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bitzer</surname>
                    <given-names>Graham J.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                  <xref rid="aff2" ref-type="aff">
                    <sup>b</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>DeJong</surname>
                    <given-names>Megan A.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                  <xref rid="aff2" ref-type="aff">
                    <sup>b</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5736-0005</contrib-id>
                  <name>
                    <surname>Kang</surname>
                    <given-names>Jason</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                  <xref rid="aff2" ref-type="aff">
                    <sup>b</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wong</surname>
                    <given-names>Ting Y.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                  <xref rid="aff2" ref-type="aff">
                    <sup>b</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wolf</surname>
                    <given-names>M. Allison</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                  <xref rid="aff2" ref-type="aff">
                    <sup>b</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bevere</surname>
                    <given-names>Justin R.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                  <xref rid="aff2" ref-type="aff">
                    <sup>b</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3250-3636</contrib-id>
                  <name>
                    <surname>Barbier</surname>
                    <given-names>Mariette</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                  <xref rid="aff2" ref-type="aff">
                    <sup>b</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3140-402X</contrib-id>
                  <name>
                    <surname>Damron</surname>
                    <given-names>F. Heath</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                  <xref rid="aff2" ref-type="aff">
                    <sup>b</sup>
                  </xref>
                  <email>fdamron@hsc.wvu.edu</email>
                </contrib>
                <aff id="aff1">
                  <label>a</label>
                  <addr-line>Department of Microbiology, Immunology and Cell Biology, School of Medicine, <institution-wrap><institution>West Virginia University</institution><institution-id institution-id-type="grid">grid.268154.c</institution-id></institution-wrap>, Morgantown, West Virginia, USA</addr-line>
                </aff>
                <aff id="aff2">
                  <label>b</label>
                  <addr-line>Vaccine Development Center, <institution-wrap><institution>West Virginia University</institution><institution-id institution-id-type="grid">grid.268154.c</institution-id></institution-wrap> Health Sciences Center, Morgantown, West Virginia, USA</addr-line>
                </aff>
              </contrib-group>
              <contrib-group>
                <contrib contrib-type="editor">
                  <role>Editor</role>
                  <name>
                    <surname>Palmer</surname>
                    <given-names>Guy H.</given-names>
                  </name>
                  <aff>Washington State University</aff>
                </contrib>
              </contrib-group>
              <author-notes>
                <fn fn-type="other">
                  <p>For a companion article on this topic, see <ext-link xlink:href="https://doi.org/10.1128/IAI.00304-21" ext-link-type="uri">https://doi.org/10.1128/IAI.00304-21</ext-link>.</p>
                </fn>
                <fn fn-type="other">
                  <p><bold>Citation</bold> Hall JM, Bitzer GJ, DeJong MA, Kang J, Wong TY, Wolf MA, Bevere JR, Barbier M, Damron FH. 2021. Mucosal immunization with DTaP confers protection against <italic toggle="yes">Bordetella pertussis</italic> infection and cough in Sprague-Dawley rats. Infect Immun 89:e00346-21. <ext-link xlink:href="https://doi.org/10.1128/IAI.00346-21" ext-link-type="uri">https://doi.org/10.1128/IAI.00346-21</ext-link>.</p>
                </fn>
              </author-notes>
              <pub-date publication-format="electronic" date-type="preprint">
                <day>13</day>
                <month>9</month>
                <year>2021</year>
              </pub-date>
              <pub-date publication-format="electronic" date-type="pub">
                <day>16</day>
                <month>11</month>
                <year>2021</year>
              </pub-date>
              <pub-date publication-format="electronic" date-type="collection">
                <month>12</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>16</day>
                <month>11</month>
                <year>2021</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>89</volume>
              <issue>12</issue>
              <elocation-id>e00346-21</elocation-id>
              <history>
                <date date-type="received">
                  <day>18</day>
                  <month>6</month>
                  <year>2021</year>
                </date>
                <date date-type="rev-request">
                  <day>4</day>
                  <month>8</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>20</day>
                  <month>8</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright © 2021 Hall et al.</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Hall et al.</copyright-holder>
                <ali:free_to_read start_date="2021-11-16"/>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="iai.00346-21.pdf"/>
              <abstract>
                <title>ABSTRACT</title>
                <p>Pertussis is a respiratory disease caused by the Gram-negative pathogen, <named-content content-type="genus-species">Bordetella pertussis</named-content>. The transition from a whole-cell pertussis vaccine (wP and DTP) to an acellular pertussis vaccine (aP, DTaP, and Tdap) correlates with an increase in pertussis cases, despite widespread vaccine implementation and coverage, and it is now appreciated that the protection provided by aP rapidly wanes. To recapitulate the localized immunity observed from natural infection, mucosal vaccination with aP was explored using the coughing rat model of pertussis. Overall, our goal was to evaluate the route of vaccination in the coughing rat model of pertussis. Immunity induced by both oral gavage and intranasal vaccination of aP in <italic toggle="yes">B. pertussis</italic> challenged rats over a 9-day infection was compared to intramuscular wP (IM-wP)- and IM-aP-immunized rats that were used as positive controls. Our data demonstrate that mucosal immunization of aP resulted in the production of anti-<italic toggle="yes">B. pertussis</italic> IgG antibody titers similar to IM-wP- and IM-aP-vaccinated controls postchallenge. IN-aP also induced anti-<italic toggle="yes">B. pertussis</italic> IgA antibodies in the nasal cavity. Immunization with IM-wP, IM-aP, IN-aP, and OG-aP immunization protected against <italic toggle="yes">B. pertussis</italic>-induced cough, whereas OG-aP immunization did not protect against respiratory distress. Mucosal immunization by both intranasal and oral gavage administration protected against acute inflammation and decreased bacterial burden in the lung compared to mock-vaccinated challenge rats. The data presented in this study suggest that mucosal vaccination with aP can induce a mucosal immune response and provide protection against <italic toggle="yes">B. pertussis</italic> challenge. This study highlights the potential benefits and uses of the coughing rat model of pertussis; however, further questions regarding waning immunity still require additional investigation.</p>
              </abstract>
              <kwd-group>
                <title>KEYWORDS</title>
                <kwd>
                  <italic toggle="yes">Bordetella pertussis</italic>
                </kwd>
                <kwd>DTaP</kwd>
                <kwd>immunization</kwd>
                <kwd>mucosal</kwd>
                <kwd>pertussis</kwd>
                <kwd>plethysmography</kwd>
                <kwd>rats</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group award-type="grant" id="award1">
                  <funding-source id="GS1">
                    <institution-wrap>
                      <institution>Division of Science and Research, WV Higherr Education Policy Commission</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>HEPC.dsr.18.6</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Damron</surname>
                      <given-names>F. Heath</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group award-type="grant" id="award2">
                  <funding-source id="GS2">
                    <institution-wrap>
                      <institution>HHS | Centers for Disease Control and Prevention (CDC)</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000030</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>75D301-19-R-67835</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Damron</surname>
                      <given-names>F. Heath</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group award-type="grant" id="award3">
                  <funding-source id="GS3">
                    <institution-wrap>
                      <institution>HHS | National Institutes of Health (NIH)</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000002</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>R01AI137155</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Damron</surname>
                      <given-names>F. Heath</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="8"/>
                <table-count count="0"/>
                <equation-count count="0"/>
                <ref-count count="78"/>
                <page-count count="19"/>
                <word-count count="12881"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>December 2021</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="s1">
              <title>INTRODUCTION</title>
              <p>Infection of the respiratory mucosa by the Gram-negative bacterium <named-content content-type="genus-species">Bordetella pertussis</named-content> (<italic toggle="yes">B. pertussis</italic>) causes the disease known as pertussis (whooping cough) (<xref rid="B1" ref-type="bibr">1</xref>). Clinical manifestations of pertussis are characterized by paroxysmal cough, hypertension, leukocytosis, and—in severe cases—death, particularly in infants who have yet to receive their first vaccine dose (<xref rid="B2" ref-type="bibr">2</xref><xref rid="B3" ref-type="bibr">–</xref><xref rid="B4" ref-type="bibr">4</xref>). Before pertussis vaccines were introduced in the United States, pertussis led to approximately 200,000 deaths annually (<xref rid="B5" ref-type="bibr">5</xref>). Largely, this disease has been under control by the use of diphtheria tetanus whole-cell pertussis (DTP and wP) and acellular pertussis (DTaP, Tdap, and aP) vaccines. DTP was introduced in the 1940s and 1950s and was largely effective in decreasing pertussis incidence (<xref rid="B6" ref-type="bibr">6</xref>). Due to the robust immune response and reactogenicity concerns, developed countries converted to the use of DTaP in the 1990s (<xref rid="B2" ref-type="bibr">2</xref>).</p>
              <p>Since the introduction of the aP vaccine, pertussis cases have been increasing, despite high vaccine coverage. It has been hypothesized that the increase in pertussis cases can be attributed to waning immunity from DTaP and Tdap vaccination, vaccine-driven evolution of <italic toggle="yes">B. pertussis</italic> strains, increased surveillance of pertussis, increased asymptomatic transmission, and improved PCR-based molecular identification of cases (<xref rid="B7" ref-type="bibr">7</xref><xref rid="B8" ref-type="bibr">–</xref><xref rid="B13" ref-type="bibr">13</xref>). Infant baboons vaccinated with DTaP (one human dose administered at 2, 4, and 6 months of age) were still colonized after experimental <italic toggle="yes">B. pertussis</italic> challenge in addition to subsequent transmission to naive baboons (<xref rid="B14" ref-type="bibr">14</xref>). In the same study, Warfel et al. showed that convalescent baboons that cleared a prior <italic toggle="yes">B. pertussis</italic> infection were not colonized after rechallenge of <italic toggle="yes">B. pertussis</italic> 1 month later (<xref rid="B14" ref-type="bibr">14</xref>). In humans, studies suggest that convalescent immunity can confer protection for approximately 4 to 20 years (<xref rid="B15" ref-type="bibr">15</xref>), while DTaP immunity falls short, lasting on average 4 to 12 years (<xref rid="B15" ref-type="bibr">15</xref>). Overall, these data demonstrated that immunity induced through natural infection can generate longer-lasting protection that also elicits pathogen clearance. Since <italic toggle="yes">B. pertussis</italic> is a respiratory pathogen, it can be hypothesized by many in the field that generating an immune response at the respiratory mucosa is necessary for protection against pertussis.</p>
              <p>Infection with <italic toggle="yes">B. pertussis</italic> localized to respiratory epithelium primes the immune response against subsequent <italic toggle="yes">B. pertussis</italic> infection by recruiting antibody-producing cells and tissue-resident memory T cells (Trms) (<xref rid="B16" ref-type="bibr">16</xref>). Bacteria invading mucosal surfaces can induce inflammation, resulting in the subsequent production of IgA antibodies (<xref rid="B17" ref-type="bibr">17</xref>). Patients previously infected with <italic toggle="yes">B. pertussis</italic> have developed IgA antibody titers in their nasal secretions (<xref rid="B18" ref-type="bibr">18</xref>). In addition, anti-<italic toggle="yes">B. pertussis</italic> IgA antibodies from patients who have convalesced from <italic toggle="yes">B. pertussis</italic> infection inhibit bacterial attachment <italic toggle="yes">in vitro</italic> and increase <italic toggle="yes">B. pertussis</italic> uptake and killing by human polymorphonuclear leukocytes (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>). Convalescent humans also generate <italic toggle="yes">B. pertussis</italic>-specific IgG antibody titers that correlate with protection (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>). <italic toggle="yes">B. pertussis</italic>-infected mice generate <italic toggle="yes">B. pertussis</italic>-specific CD4<sup>+</sup> T cells in the lung that secrete gamma interferon and interleukin-17 (IL-17) (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>). In mice, <italic toggle="yes">B. pertussis</italic> infection induced Trms in the lung and were associated with pathogen clearance (<xref rid="B16" ref-type="bibr">16</xref>). Nonhuman primates previously infected with <italic toggle="yes">B. pertussis</italic> generate both Th1 and Th17 memory cells that are still detected 2 years postinfection (<xref rid="B25" ref-type="bibr">25</xref>). To induce a similar protective immune response that is observed during natural infection, mucosal vaccination has recently been investigated by our laboratory and others (<xref rid="B26" ref-type="bibr">26</xref><xref rid="B27" ref-type="bibr">–</xref><xref rid="B28" ref-type="bibr">28</xref>).</p>
              <p>Mucosal immunization has been rarely used as a vaccination strategy to generate a protective immune response against pertussis in clinical and preclinical models. Oral vaccination with wP induced the production of <italic toggle="yes">B. pertussis</italic>-specific antibody titers in both the saliva and the sera of newborns (<xref rid="B29" ref-type="bibr">29</xref>). In a subsequent study in 1985, oral immunization with 10<sup>12</sup> CFU of killed <italic toggle="yes">B. pertussis</italic> led to the induction of antibody titers in the saliva and sera of newborns (<xref rid="B30" ref-type="bibr">30</xref>). The frequency of pertussis was lower in orally vaccinated newborns during the first year of life compared to newborns who were unvaccinated, although this difference disappeared by the end of the year (<xref rid="B30" ref-type="bibr">30</xref>). In mice, oral administration of the attenuated bacterial vectors <named-content content-type="genus-species">Salmonella</named-content> Typhimurium and <named-content content-type="genus-species">Escherichia coli</named-content> expressing the <italic toggle="yes">B. pertussis</italic> antigen, filamentous hemagglutinin (FHA), results in the production of anti-FHA IgA antibody titers in the lung (<xref rid="B31" ref-type="bibr">31</xref>). Intranasal (i.n.) immunization of a live attenuated vaccine strain of <italic toggle="yes">B. pertussis</italic>, BPZE1, was protective both in preclinical and clinical studies (<xref rid="B32" ref-type="bibr">32</xref><xref rid="B33" ref-type="bibr">–</xref><xref rid="B35" ref-type="bibr">35</xref>). Previously, our lab has shown that i.n. immunization of DTaP can induce a protective immune response in mice (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>). Boehm et al. illustrated that i.n. vaccination of DTaP with or without the addition of the adjuvant curdlan induces both anti-<italic toggle="yes">B. pertussis</italic> and anti-pertussis toxin (anti-PT) IgG antibody titers, as well as <italic toggle="yes">B. pertussis</italic>-specific IgA in the lung (<xref rid="B27" ref-type="bibr">27</xref>). A follow-up study performed by Wolf et al. suggested that i.n. aP (IN-aP) vaccination is protective through the induction of humoral responses 6 months after booster vaccination and challenge (<xref rid="B28" ref-type="bibr">28</xref>). Mounting evidence supports that mucosal immunization can be protective against <italic toggle="yes">B. pertussis</italic> colonization, but unfortunately murine studies lack the ability to evaluate one the of hallmark symptoms of pertussis, <italic toggle="yes">B. pertussis</italic>-induced coughing.</p>
              <p>The rat model of pertussis has been utilized to characterize <italic toggle="yes">B. pertussis</italic> pathogenesis and evaluate coughing manifestation from <italic toggle="yes">B. pertussis</italic> infection (<xref rid="B36" ref-type="bibr">36</xref><xref rid="B37" ref-type="bibr">–</xref><xref rid="B42" ref-type="bibr">42</xref>). Only a few studies have been performed investigating vaccine efficacy in the coughing rat model of pertussis. Hall et al. demonstrated that the SmithKline Beecham three-component aP vaccine (detoxified PT [PTd], FHA, and a 69-kDa antigen, presumably pertactin [PRN]), the Connaught five-component vaccine (PTd, FHA, agglutinins 2+3 [fimbriae], and PRN), and Evans whole-cell pertussis vaccine protected against cough upon intrabronchial <italic toggle="yes">B. pertussis</italic> challenge (<xref rid="B41" ref-type="bibr">41</xref>). Rats administered a single human dose of DTP had a lower incidence of coughing following <italic toggle="yes">B. pertussis</italic> challenge (<xref rid="B39" ref-type="bibr">39</xref>). In the present study, our overarching goal was to evaluate various routes of immunization of DTaP in the coughing rat model of pertussis. We hypothesized that both oral and i.n. vaccination would protect against bacterial burden upon challenge, as well as against <italic toggle="yes">B. pertussis</italic>-induced coughing, in the rat model of pertussis by generating a protective immune response at the site of infection. To test this hypothesis, we i.n. and oral gavage (o.g.) vaccinated and challenged Sprague-Dawley rats with a 1/5 human dose of DTaP. Intramuscular wP (IM-wP)- and IM-aP-vaccinated and <italic toggle="yes">B. pertussis</italic>-challenged rats were used as positive controls to compare vaccine-mediated immunity since intramuscular (i.m.) administration of DTaP is the current route of vaccine administration.</p>
              <p>In our study, we aimed to use the rat model of pertussis to measure protection induced from mucosal vaccination of DTaP. By utilizing the coughing rat model of pertussis, protection against bacterial burden in the respiratory tract and prevention of <italic toggle="yes">B. pertussis</italic> induced cough after immunization was critically analyzed. We also focused on evaluating the serological responses regarding vaccination followed by <italic toggle="yes">B. pertussis</italic> challenge. Our data support the hypothesis that protection is afforded by mucosal immunization with DTaP. We found that i.n. and o.g. immunization with DTaP not only induced systemic anti-<italic toggle="yes">B. pertussis</italic> IgG antibodies but also induced mucosal anti-<italic toggle="yes">B. pertussis</italic> IgA antibodies. These data suggest that oral vaccination of DTaP can generate a humoral immune response at the respiratory mucosa in rats. IN-aP and o.g. AP (OG-aP) was also capable of protecting against <italic toggle="yes">B. pertussis-</italic>induced cough. Furthermore, mucosal vaccination protected against bacterial burden in the respiratory tract. In conclusion, we highlight here (i) the benefits of using the coughing rat model of pertussis and (ii) the prospect of mucosal vaccination with <italic toggle="yes">B. pertussis</italic> vaccines.</p>
            </sec>
            <sec sec-type="results" id="s2">
              <title>RESULTS</title>
              <sec id="s2-1">
                <title>Intranasal immunization induces systemic anti-<italic toggle="yes">B. pertussis</italic> IgG and anti-PT IgM and IgG antibody titers following booster immunization.</title>
                <p>We hypothesized that IN-aP and OG-aP immunization would induce systemic IgM and IgG antibodies, since mucosal immunization stimulates the induction of both systemic and mucosal antibodies (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B30" ref-type="bibr">30</xref>). To test this hypothesis, 3-week-old Sprague-Dawley rats were IM-wP, IM-aP, IN-aP, and OG-aP immunized, followed by a booster immunization at 6 weeks of age with the same corresponding vaccine (see Fig. S1). Mucosal and systemic antibodies were measured over the course of vaccination (see Fig. S1). Minimal differences in antibody titers prior to booster vaccination were observed for all immunized groups (<xref rid="F1" ref-type="fig">Fig. 1</xref>). Compared to all other groups, IM-wP vaccination induced a significant increase of anti-<italic toggle="yes">B. pertussis</italic> IgM in the serum 1 week after booster vaccination (<xref rid="F1" ref-type="fig">Fig. 1A</xref>). IM-wP-, IM-aP-, and IN-aP-vaccinated rats had a significant increase in anti-<italic toggle="yes">B. pertussis</italic> IgG antibody titers following booster immunization compared to mock-vaccinated challenged (MVC) rats (<xref rid="F1" ref-type="fig">Fig. 1B</xref>). Rats vaccinated using IM-aP experienced a significant increase in anti-PT IgM antibody titers 1 week after the booster vaccine compared to the MVC control (<xref rid="F1" ref-type="fig">Fig. 1C</xref>). IM-aP- and IN-aP-vaccinated rats had a significant increase in anti-PT IgM antibodies compared to IM-wP- and OG-aP-vaccinated rats (<xref rid="F1" ref-type="fig">Fig. 1C</xref>). This same trend was also observed in measuring anti-PT IgG antibodies (<xref rid="F1" ref-type="fig">Fig. 1D</xref>). We observed a significant 4-log increase in anti-PT IgG antibodies in IM-aP- and IN-aP-immunized rats compared to our MVC, IM-wP, and OG-aP groups (<xref rid="F1" ref-type="fig">Fig. 1D</xref>). Here, our data show that after booster immunization, IN-aP-vaccinated rats developed systemic anti-<italic toggle="yes">B. pertussis</italic> IgG and anti-PT IgG and IgM antibody titers.</p>
                <fig position="float" id="F1">
                  <label>FIG 1</label>
                  <caption>
                    <p>i.n. booster vaccination induces systemic anti-<italic toggle="yes">B. pertussis</italic> (anti-<italic toggle="yes">Bp</italic>) and anti-PT antibody titers. At 1 and 2 weeks after prime immunization and at 1 week after boost blood was collected via the saphenous vein, and anti-<italic toggle="yes">Bp</italic> and anti PT IgM (A and C)- and IgG (B and D)-specific antibodies were measured. The results are shown on a log scale and as means ± the standard errors of the mean (SEM; <italic toggle="yes">n</italic> = 3 to 8). The dotted line represents the limit of detection. <italic toggle="yes">*</italic>, <italic toggle="yes">P</italic> &lt; 0.05. (<italic toggle="yes">n</italic> = 4 to 8). <italic toggle="yes">P</italic> values were determined by two-way ANOVA with Tukey’s <italic toggle="yes">post hoc</italic> test compared between groups. Asterisks (*) under each graph annotate the significance between labeled groups under the <italic toggle="yes">y</italic> axis and the group under the corresponding bar. Grayed-out boxes indicate that no stats were calculated.</p>
                  </caption>
                  <graphic xlink:href="iai.00346-21-f001" position="float"/>
                </fig>
              </sec>
              <sec id="s2-2">
                <title>Mucosal vaccination protects against cough from <italic toggle="yes">B. pertussis</italic>-infected rats.</title>
                <p>In 2014, Warfel et al. showed that aP vaccination was protective against pertussis disease but failed to protect against colonization and transmission of <italic toggle="yes">B. pertussis</italic> in the nonhuman primate model (<xref rid="B14" ref-type="bibr">14</xref>). We hypothesized that mucosal vaccination with DTaP would protect against <italic toggle="yes">B. pertussis</italic>-induced cough by eliciting a protective immune response at the respiratory mucosa. To test this hypothesis, vaccinated rats were subsequently i.n. challenged with <italic toggle="yes">B. pertussis</italic> 2-weeks after booster vaccine administration (see Fig. S1). Every evening postchallenge, coughs were counted using whole-body plethysmography (WBP). MVC rats averaged a total of five coughs or less during monitoring for the first 5 days of infection (<xref rid="F2" ref-type="fig">Fig. 2A</xref>). At days 6 and 7 postchallenge, average coughs per 15 min increased to more than 30 coughs (<xref rid="F2" ref-type="fig">Fig. 2A</xref>). There was a significant decrease in coughs for rats vaccinated with IM-wP, IM-aP, IN-aP, and OG-aP at days 6 and 7 postchallenge compared to MVC rats (<xref rid="F2" ref-type="fig">Fig. 2B</xref> to <xref rid="F2" ref-type="fig">E</xref>). On average, rats vaccinated with IM-wP coughed ∼6 coughs per 15 min each day (<xref rid="F2" ref-type="fig">Fig. 2B</xref>). Rats vaccinated with IM-aP on average coughed twice per 15 min each day (<xref rid="F2" ref-type="fig">Fig. 2C</xref>). IN-aP-immunized rats on average coughed three times per 15 min each day, while OG-aP-vaccinated rats coughed on average four times per 15 min each day (<xref rid="F2" ref-type="fig">Fig. 2D</xref> and <xref rid="F2" ref-type="fig">E</xref>). To compare the average total number of coughs each day postchallenge, we calculated the total number of coughs for each group per animal. We observed a significant decrease in total number of coughs in rats vaccinated with IM-aP (14 coughs) and IN-aP (27 coughs) compared to MVC rats (102 coughs) over the 9-day infection (<xref rid="F2" ref-type="fig">Fig. 2F</xref>). OG-aP-immunized rats coughed, on average, 35 times (<xref rid="F2" ref-type="fig">Fig. 2F</xref>). Our data demonstrate that mucosal vaccination in rats protects against <italic toggle="yes">B. pertussis</italic>-induced cough.</p>
                <fig position="float" id="F2">
                  <label>FIG 2</label>
                  <caption>
                    <p>Intranasal and oral vaccination of acellular pertussis vaccine decreases cough in <named-content content-type="genus-species">B. pertussis</named-content>-infected rats. Coughs were counted every day of the 9-day infection using WBP. Coughs were counted for mock-vaccinated challenge rats (A) and for IM-wP (B)-, IM-aP (C)-, IN-aP (D)-, and OG-aP (E)-vaccinated and challenged rats. (F) To assess any potential differences between vaccine groups over the entire course of infection, the average total numbers of coughs for each rat per group were compared. The results are shown as means ± the SEM (<italic toggle="yes">n </italic>= 3 to 4). <italic toggle="yes">P</italic> values were determined by two-way ANOVA with Dunnett’s <italic toggle="yes">post hoc</italic> test and one-way ANOVA with Dunnett <italic toggle="yes">post hoc</italic> test for total cough count (*, <italic toggle="yes">P </italic>&lt;<italic toggle="yes"> </italic>0.05; *<italic toggle="yes">*</italic>, <italic toggle="yes">P </italic>&lt;<italic toggle="yes"> </italic>0.01; **<italic toggle="yes">*</italic>, <italic toggle="yes">P </italic>&lt;<italic toggle="yes"> </italic>0.001; ***<italic toggle="yes">*</italic>, <italic toggle="yes">P </italic>&lt;<italic toggle="yes"> </italic>0.0001 [compared to the mock-vaccinated challenge control group]).</p>
                  </caption>
                  <graphic xlink:href="iai.00346-21-f002" position="float"/>
                </fig>
              </sec>
              <sec id="s2-3">
                <title>Intranasal vaccination protects against pulmonary distress.</title>
                <p>Our previous work has shown that <italic toggle="yes">B. pertussis</italic>-infected rats showed a significant increase in pulmonary distress after challenge (<xref rid="B43" ref-type="bibr">43</xref>). Pulmonary distress can be evaluated by calculating the enhanced pause (PenH). PenH functions as a representation of bronchoconstriction, taking into consideration the timing between early and late expiration and the estimated maximum inspiratory and expiratory flows per breath. We hypothesized that mucosal vaccination would protect against <italic toggle="yes">B. pertussis</italic>-induced pulmonary distress. Here, rats vaccinated with IM-wP, IM-aP, and IN-aP had a significant decrease in PenH compared to the MVC control group at days 5 and 7 postchallenge (<xref rid="F3" ref-type="fig">Fig. 3A, D, E</xref>, and <xref rid="F3" ref-type="fig">F</xref>). Rats vaccinated IM-aP and IN-aP also experienced a significant decrease in PenH at day 6 postchallenge compared to MVC rats (<xref rid="F3" ref-type="fig">Fig. 3A, C, D</xref>, and <xref rid="F3" ref-type="fig">F</xref>). However, there was no significant decrease in PenH in OG-aP-vaccinated rats compared to MVC, suggesting that the induced immune response is not sufficient enough to protect rats from <italic toggle="yes">B. pertussis</italic>-induced respiratory distress (<xref rid="F3" ref-type="fig">Fig. 3E</xref>). Other respiratory parameters were also measured using WBP (see Fig. S2). In brief, we observed that rats vaccinated with IM-wP, IM-aP, and IN-aP had a significant decrease in pause (PAU) compared to the MVC control group, which is another indicator of bronchiole restriction (see Fig. S2B). Rats vaccinated with the aP vaccine regardless of route also showed a significant decrease in tidal volume (TVb) compared to MVC rats, which could be crudely associated with inflammation (see Fig. S2D). Overall, our data demonstrated that IN-aP vaccination decreases pulmonary distress of <italic toggle="yes">B. pertussis</italic>-infected rats.</p>
                <fig position="float" id="F3">
                  <label>FIG 3</label>
                  <caption>
                    <p>Intranasal vaccination decreases the pulmonary restriction of <named-content content-type="genus-species">B. pertussis</named-content>-infected rats. Bronchiole restriction was measured over the course of infection by WBP. Bronchiole restriction was determined by the factor Penh for mock-vaccinated challenge rats (A) and for IM-wP (B)-, IM-aP (C)-, IN-aP (D)-, and OG-aP (E)-vaccinated and challenged rats. The results are shown as means ± the SEM (<italic toggle="yes">n </italic>=<italic toggle="yes"> </italic>3 to 4). (F) Differences observed between groups at days 5 to 7 postchallenge. <italic toggle="yes">P</italic> values were determined by two-way ANOVA with Dunnett’s <italic toggle="yes">post hoc</italic> test (*, <italic toggle="yes">P </italic>&lt;<italic toggle="yes"> </italic>0.05; *<italic toggle="yes">*</italic>, <italic toggle="yes">P </italic>&lt;<italic toggle="yes"> </italic>0.01; **<italic toggle="yes">*</italic>, <italic toggle="yes">P</italic> &lt; 0.001 [compared to the mock-vaccinated challenge group]).</p>
                  </caption>
                  <graphic xlink:href="iai.00346-21-f003" position="float"/>
                </fig>
              </sec>
              <sec id="s2-4">
                <title>Mucosal immunization induces production of <italic toggle="yes">B. pertussis</italic>-specific antibodies in serum, while i.n. immunization also induces PT-specific antibodies in serum.</title>
                <p>Next, we wanted to measure systemic antibody responses to <italic toggle="yes">B. pertussis</italic> and PT after challenge. IM-wP-vaccinated rats had a slight increase in anti-<italic toggle="yes">B. pertussis</italic> IgM antibodies compared to all other vaccinated groups, albeit not significant (<xref rid="F4" ref-type="fig">Fig. 4A</xref>). We observed a significant increase in anti-<italic toggle="yes">B. pertussis</italic> IgG antibody titers in IM-wP-, IM-aP-, and IN-aP-vaccinated rats compared to the MVC at day 1 postchallenge (<xref rid="F4" ref-type="fig">Fig. 4B</xref>). At day 9 postchallenge, all vaccinated rats had a significant increase of anti-<italic toggle="yes">B. pertussis</italic> IgG antibody titers compared to the MVC control (<xref rid="F4" ref-type="fig">Fig. 4B</xref>). After <italic toggle="yes">B. pertussis</italic> challenge, IM-aP- and IN-aP-immunized rats had a significant increase in anti-PT IgM antibodies compared to IM-wP-immunized rats and MVC controls. (<xref rid="F4" ref-type="fig">Fig. 4C</xref>). Similar results were observed in measuring anti-PT IgG titers (<xref rid="F4" ref-type="fig">Fig. 4D</xref>). IM-aP and IN-aP vaccination induced a significant increase in anti-PT IgG antibody titers compared to MVC-, IM-wP-, and OG-aP-immunized rats after booster vaccination and at days 1 and 9 postchallenge (<xref rid="F4" ref-type="fig">Fig. 4D</xref>). Although not significant, two of the OG-aP-immunized rats had detectable anti-PT IgG antibody titers in the serum at day 9 postchallenge (<xref rid="F4" ref-type="fig">Fig. 4D</xref>). An enzyme-linked immune absorbent spot (ELISpot) assay was used to determine the number of <italic toggle="yes">B. pertussis</italic>-specific IgG cells in the bone marrow at day 9 postchallenge. There was an increase in the number of <italic toggle="yes">B. pertussis</italic>-specific IgG cells in the bone marrow in all vaccination groups compared to the MVC control; however, the only significant increase in <italic toggle="yes">B. pertussis</italic>-specific IgG-producing cells in the bone marrow was detected in IM-wP-vaccinated rats (see Fig. S3). Our data indicate that mucosal vaccination via i.n. and o.g. immunization induced <italic toggle="yes">B. pertussis</italic>-specific IgG antibody responses.</p>
                <fig position="float" id="F4">
                  <label>FIG 4</label>
                  <caption>
                    <p>Mucosal vaccination induces the production of anti-<italic toggle="yes">B. pertussis</italic> IgG, whereas i.n. immunization also induces both anti-PT IgM and IgG antibodies. ELISAs were used to determine and compare the induced serological responses from vaccinated and challenge rats in the serum. Both IgM (A and C) and IgG (B and D) serum antibody titers from immunized and challenged rats were measured postchallenge. The dotted line represents the limit of detection. The results are shown on a log scale as means ± the SEM (*, <italic toggle="yes">P</italic> &lt; 0.05; <italic toggle="yes">n </italic>=<italic toggle="yes"> </italic>4). <italic toggle="yes">P</italic> values were determined by two-way ANOVA with Tukey’s <italic toggle="yes">post hoc</italic> test compared between groups. Asterisks (*) under each graph annotate the significance between labeled group under the <italic toggle="yes">y</italic> axis and the group under the corresponding bar. Grayed-out boxes indicate that no stats were calculated.</p>
                  </caption>
                  <graphic xlink:href="iai.00346-21-f004" position="float"/>
                </fig>
              </sec>
              <sec id="s2-5">
                <title>Intranasal immunization induces production of <italic toggle="yes">B. pertussis</italic>-specific IgA antibodies in the nasal cavity.</title>
                <p>In humans, previous <italic toggle="yes">B. pertussis</italic> infection leads to anti-<italic toggle="yes">B. pertussis</italic> IgA antibodies in nasal secretions (<xref rid="B18" ref-type="bibr">18</xref>). IgA antibodies to <italic toggle="yes">B. pertussis</italic> play a role in the inhibition of <italic toggle="yes">B. pertussis</italic> attachment <italic toggle="yes">in vitro</italic> to epithelial cells (<xref rid="B19" ref-type="bibr">19</xref>). Here, we investigated whether i.n. and o.g. immunization of DTaP would induce mucosal IgA antibodies in the lung and/or the nasal cavity. In the lung, three of the four IN-aP-vaccinated rats had detectable anti-<italic toggle="yes">B. pertussis</italic> IgA antibodies at day 1 postchallenge, although this was not significant (<xref rid="F5" ref-type="fig">Fig. 5A</xref>). We did not detect anti-<italic toggle="yes">B. pertussis</italic> IgA antibody titers at day 1 postchallenge in the lungs of IM-wP-, IM-aP-, or OG-aP-vaccinated rats (<xref rid="F5" ref-type="fig">Fig. 5A</xref>). It is possible that we needed to use a larger amount of serum or enhanced secondary detection methods to detect IgA at day 1. Low levels of anti-<italic toggle="yes">B. pertussis</italic> IgA titers were measured in all vaccinated groups at day 9 postchallenge, although this was not significant compared to the MVC control (<xref rid="F5" ref-type="fig">Fig. 5A</xref>). The same trend was observed in the lung when we measured anti-PT IgA titers at day 1 postchallenge (<xref rid="F5" ref-type="fig">Fig. 5B</xref>). At day 9 postchallenge, 50% of the IN-aP-vaccinated rats and 25% of the OG-aP-vaccinated rats had detectable anti-PT IgA (<xref rid="F5" ref-type="fig">Fig. 5B</xref>). In the nasal cavity, only one IN-aP-vaccinated rat had detectable anti-<italic toggle="yes">B. pertussis</italic> IgA antibody titers; however, we did measure a significant increase in anti-<italic toggle="yes">B. pertussis</italic> IgA antibodies in IN-aP-immunized rats at day 9 postchallenge compared to the MVC-, IM-wP-, IM-aP-, and OG-aP-immunized rats (<xref rid="F5" ref-type="fig">Fig. 5C</xref>). Only one IN-aP- and one OG-aP-vaccinated rat had detectable amounts of anti-PT IgA in the nasal cavity at day 9 postchallenge (<xref rid="F5" ref-type="fig">Fig. 5D</xref>). Overall, our data reveal that IN-aP immunization can induce IgA antibodies in the nasal cavities of rats.</p>
                <fig position="float" id="F5">
                  <label>FIG 5</label>
                  <caption>
                    <p>Intranasal immunization elicits the production of anti-<italic toggle="yes">B. pertussis</italic> IgA in the respiratory tract. ELISA was used to analyze antibodies in the lung (A and B) and nasal cavity (C and D) from lung homogenate supernatant and PBS flushed through the nasal cavity from vaccinated and challenge rats at days 1 and 9 postchallenge. IgA titers were determined against pertussis toxin and <named-content content-type="genus-species">B. pertussis</named-content>. The dotted line represents the limit of detection. The results are shown on a log scale as a means ± the SEM (<italic toggle="yes">n</italic> = 3 to 4; *<italic toggle="yes">*</italic>, <italic toggle="yes">P</italic> &lt; 0.01; ***<italic toggle="yes">*</italic>, <italic toggle="yes">P</italic> &lt; 0.0001). <italic toggle="yes">P</italic> values were determined by the Kruskal-Wallis test, using Dunn’s <italic toggle="yes">post hoc</italic> test to compare between groups.</p>
                  </caption>
                  <graphic xlink:href="iai.00346-21-f005" position="float"/>
                </fig>
              </sec>
              <sec id="s2-6">
                <title>Mucosal immunization protects against acute inflammation in the lung.</title>
                <p>Our previous rat challenge study illustrated that i.n. <italic toggle="yes">B. pertussis</italic> challenge gave rise to both neutrophilic and mononuclear infiltration into the rat lung (<xref rid="B43" ref-type="bibr">43</xref>). Here, we used histology to assess whether mucosal immunization would protect against <italic toggle="yes">B. pertussis</italic>-induced inflammation in the lung. At day 1 postchallenge, no differences in neutrophilic inflammation were observed; however, at day 9 postchallenge, rats vaccinated with IM-aP, IN-aP, and OG-aP had significantly lower neutrophilic inflammation scores compared to the MVC rats (<xref rid="F6" ref-type="fig">Fig. 6A</xref> and <xref rid="F6" ref-type="fig">C</xref>). IN-aP-immunized rats showed an increase in mononuclear infiltration score at day 1 postchallenge (<xref rid="F6" ref-type="fig">Fig. 6B</xref> and <xref rid="F6" ref-type="fig">D</xref>). There were no observed differences in mononuclear infiltration score in vaccinated rats compared to MVC rats at day 9 postchallenge (<xref rid="F6" ref-type="fig">Fig. 6D</xref>). There were no differences in lung weight, which can be used as a crude measurement for lung inflammation, following <italic toggle="yes">B. pertussis</italic> challenge (see Fig. S4A). We did observe a significant increase in percent body weight change in IM-wP-vaccinated rats compared to MVC control rats, suggesting that wP protects against the weight loss observed in nonvaccinated challenged rats (see Fig. S4B). Our observations suggest that that mucosal vaccination protects against <italic toggle="yes">B. pertussis</italic>-induced inflammation in the lung (<xref rid="F6" ref-type="fig">Fig. 6C</xref>).</p>
                <fig position="float" id="F6">
                  <label>FIG 6</label>
                  <caption>
                    <p>Mucosal vaccination protects against acute and total inflammation in the lung of <italic toggle="yes">B. pertussis</italic>-infected Sprague-Dawley rats. After euthanasia, the left lobe of the lung was excised, sectioned, and stained with H&amp;E. Lung samples scores are based on standard qualitative toxicologic scoring criteria: 0, none; 1, minimal (rare); 2, mild (slight); 3, moderate; 4, marked; and 5, severe. (A) Representative image of acute inflammation of rat lung showing increased numbers of neutrophils and edema surrounding blood vessel (asterisk). (B) Representative image of chronic inflammation of the rat lung showing increased numbers of mononuclear cells surrounding bronchioles (asterisk). Inflammatory cells are also present in the lamina propria (arrow) and epithelium (arrowhead) of bronchioles. (C) Average acute inflammation scores of the lung are detailed by the presence of neutrophils in the parenchyma, blood vessels, and the airways. (D) Average chronic inflammation scores are distinguished by mononuclear infiltrates in the parenchyma, blood vessels, and airway of the lung. All scoring assessments were determined with no knowledge of the groups. The results are shown as means ± the SEM (<italic toggle="yes">n </italic>= 3 to 4). <italic toggle="yes">P</italic> values were determined by two-way ANOVA, followed by Dunnett’s comparison test (*, <italic toggle="yes">P </italic>&lt;<italic toggle="yes"> </italic>0.05; *<italic toggle="yes">*</italic>, <italic toggle="yes">P </italic>&lt;<italic toggle="yes"> </italic>0.01 [compared to mock challenge]).</p>
                  </caption>
                  <graphic xlink:href="iai.00346-21-f006" position="float"/>
                </fig>
              </sec>
              <sec id="s2-7">
                <title>Mucosal vaccination protects against <italic toggle="yes">B. pertussis</italic> challenge.</title>
                <p>Next, we wanted to assess whether mucosal immunization could protect against <italic toggle="yes">B. pertussis</italic> burden in the respiratory tract. The bacterial burden in the respiratory tract was determined 1 h, 1 day, and 9 days after <italic toggle="yes">B. pertussis</italic> challenge. The bacterial burden was measured at 1 h postchallenge (<italic toggle="yes">n</italic> = 2) to assess the potential bacterial loss for our original challenge dose. In the lung, trachea, and nasal lavage fluid, we measured ∼10<sup>6</sup> CFU at 1 h postchallenge (<xref rid="F7" ref-type="fig">Fig. 7A</xref> to <xref rid="F7" ref-type="fig">C</xref>). At day 1 postchallenge, there was a significant 98.5% reduction in bacterial burden in the lungs of IM-aP-immunized rats compared to MVC controls (<xref rid="F7" ref-type="fig">Fig. 7A</xref>). IM-wP-, IM-aP-, IN-aP-, and OG-aP-vaccinated rats all experienced a significant decrease in bacterial burden in the lung at day 9 postchallenge compared to MVC rats (<xref rid="F7" ref-type="fig">Fig. 7A</xref>). There was also a significant decrease in bacterial burden in the trachea at both days 1 and 9 postchallenge in all vaccinated rats compared to MVC controls (<xref rid="F7" ref-type="fig">Fig. 7B</xref>). At day 1 postchallenge, there was a significant 86 to 97% reduction in bacterial burden in all vaccinated rats compared to MVC rats in the nasal cavity (<xref rid="F7" ref-type="fig">Fig. 7C</xref>). At day 9 postchallenge, we did not measure any significant differences between groups since most of the bacteria were cleared from the nasal cavity (<xref rid="F7" ref-type="fig">Fig. 7C</xref>). Overall, we observed that IN-aP- and OG-aP-vaccinated rats showed a significant reduction in bacterial burden in the respiratory tract compared to the MVC control group at days 1 and 9 postchallenge (<xref rid="F7" ref-type="fig">Fig. 7A</xref> to <xref rid="F7" ref-type="fig">C</xref>).</p>
                <fig position="float" id="F7">
                  <label>FIG 7</label>
                  <caption>
                    <p>Oral and intranasal immunization decreased the <named-content content-type="genus-species">B. pertussis</named-content> bacterial burden in the respiratory tract. Bacteria were quantified by serially diluted CFU after vaccination and intranasal challenge. CFU counts were determined from lung homogenate (A), trachea (B), and nasal lavage (C) 1.5 h, 1 day, and 9 days after <named-content content-type="genus-species">B. pertussis</named-content> challenge. The results are shown as means ± the SEM (<italic toggle="yes">n </italic>=<italic toggle="yes"> </italic>2 to 4). <italic toggle="yes">P</italic> values were determined by one-way ANOVA with Dunnett’s <italic toggle="yes">post hoc</italic> test (*, <italic toggle="yes">P </italic>&lt;<italic toggle="yes"> </italic>0.05; *<italic toggle="yes">*</italic>, <italic toggle="yes">P </italic>&lt;<italic toggle="yes"> </italic>0.01; **<italic toggle="yes">*</italic>, <italic toggle="yes">P </italic>&lt;<italic toggle="yes"> </italic>0.001; ***<italic toggle="yes">*</italic>, <italic toggle="yes">P </italic>&lt;<italic toggle="yes"> </italic>0.0001 [compared to the mock-vaccinated challenge group]).</p>
                  </caption>
                  <graphic xlink:href="iai.00346-21-f007" position="float"/>
                </fig>
              </sec>
              <sec id="s2-8">
                <title>wP immunization induces a proinflammatory cytokine response compared to mucosally vaccinated Sprague-Dawley rats.</title>
                <p>Previous studies have shown that both wP immunization and <italic toggle="yes">B. pertussis</italic> infection induces a proinflammatory Th1/Th17 immune response, while aP immunization promotes a more Th2 skewed response (<xref rid="B44" ref-type="bibr">44</xref><xref rid="B45" ref-type="bibr">–</xref><xref rid="B50" ref-type="bibr">50</xref>). To compare cytokine responses in the coughing rat model through vaccination and challenge to the cytokine responses observed in the mouse and baboon models, we measured cytokines in the lung and serum. In the lung at day 1 postchallenge, we measured a significant 4-fold increase in IL-17 in MVC rats compared to IM-aP- and IN-aP-vaccinated rats (see Fig. S5A). At day 9 postchallenge, IM-wP-immunized rats had a significant increase in IL-17 compared to IM-aP-vaccinated, IN-aP-vaccinated, and MVC rats (see Fig. S5A). IM-wP-vaccinated rats also had a significant increase in Th1 cytokine IL-12p70 compared to MVC rats in the lung and serum at day 9 postchallenge (see Fig. S5A and B). IM-wP-vaccinated rats had a significant increase in the Th2 cytokines IL-4 and IL-13 in the serum compared to IM-aP- and IN-aP-vaccinated rats and a significant increase in IL-4 to MVC controls at day 9 postchallenge (see Fig. S5B). IM-wP-immunized rats also had a significant increase in granulocyte/colony-stimulating factor in the serum day 9 postchallenge compared to IM-aP-, IN-aP-, and OG-aP-vaccinated rats and MVC rats. Overall, we did not observe marked changes in cytokine responses between DTaP-vaccinated rats compared to the MVC control group; however, rats immunized with OG-aP did have a slight increase in IL-17, although this increase was not significant. The observed difference in cytokines levels could be from <italic toggle="yes">B. pertussis</italic> challenge rather than vaccination. The increase in acute inflammatory score in the lungs of IM-wP-immunized rats at day 9 postchallenge could be associated with the increase in proinflammatory cytokines. Graphs showing the statistical significance between cytokines in the serum and lung are included in the supplemental data (see Fig. S6 and S7). Our data show that the response to <named-content content-type="genus-species">B. pertussis</named-content> in IM-wP-immunized animals is a robust cytokine response compared to both naive and aP-vaccinated rats, which is to be expected based on work that has examined the Th17 response induced by whole-cell pertussis vaccines.</p>
                <p><italic toggle="yes">B. pertussis</italic> infection induces an increase in circulating neutrophils in the blood, as well as white blood cells and lymphocytes (<xref rid="B51" ref-type="bibr">51</xref><xref rid="B52" ref-type="bibr">–</xref><xref rid="B56" ref-type="bibr">56</xref>). In the present study, we utilized hematology and flow cytometry to evaluate these populations. Hematology analysis revealed a significant increase in blood lymphocytes in the IN-aP-vaccinated rats compared to MVC rats postchallenge; however, no other differences in white blood cell counts in the blood were observed in the other vaccinated groups (see Fig. S8A and B). At day 1 postchallenge, there was a significant decrease in circulating neutrophils in the blood of IN-aP-immunized rats compared to MVC rats (see Fig. S8C). Flow cytometry analysis revealed minimal differences in the numbers of neutrophils and B cells at days 1 and 9 postchallenge in all groups (see Fig. S8E and F). Based upon these data, subtle differences in various circulating cell populations were observed following IN-aP vaccination.</p>
              </sec>
              <sec id="s2-9">
                <title>Serological responses correlate with bacterial clearance in the respiratory tract.</title>
                <p>Currently, no definitive correlates of protection (CoP) for vaccines to protect against <italic toggle="yes">B. pertussis</italic> have been established, despite many years of research (<xref rid="B22" ref-type="bibr">22</xref>). Th17 responses, as well as Trms, correlate with strong protection in mice and baboons. Antibodies to PT/FHA/PRN do not always correlate with protection in humans. In an effort to more precisely define correlates using the rat model, we aimed to utilize the coughing phenotype and bacterial burden to identify the nature of how each vaccine protects (o.g., i.n., and i.m.; acellular or wP). Previous work in our lab performed by Wolf et al. illustrated that serum anti-<italic toggle="yes">B. pertussis</italic>, anti-FHA, and anti-PT IgG antibody titers in the serum following i.n. vaccination in mice correlated with the decrease in bacterial burden in the lung following <italic toggle="yes">B. pertussis</italic> challenge (<xref rid="B28" ref-type="bibr">28</xref>). Previous studies have shown that serum anti-<italic toggle="yes">B. pertussis</italic> IgG antibodies induced from wP vaccination correlate with protection against bacterial burden in the lungs of <italic toggle="yes">B. pertussis</italic>-challenged mice (<xref rid="B57" ref-type="bibr">57</xref>). Here, we hypothesized that antigen-specific serum IgG and mucosal IgA antibodies correlate with decreased bacterial burden and cough, since IN-aP and OG-aP vaccination induced systemic and mucosal antibody responses. To test this hypothesis, we generated correlograms to evaluate both negative and positive correlations elicited by each vaccination route. Correlograms are an analysis tool that can be used to determine whether the relationship observed between variables (i.e., bacterial burden and antibody titers) is random or not (<xref rid="B58" ref-type="bibr">58</xref>). If the relationship between the two variables is random the <italic toggle="yes">R</italic><sup>2</sup> correlation value is at or near zero (<xref rid="B58" ref-type="bibr">58</xref>). The relationship is considered correlative if the <italic toggle="yes">R</italic><sup>2</sup> value is approximately positive or negative (<xref rid="B58" ref-type="bibr">58</xref>). Significant positive nonzero correlation values demonstrate a positive correlation between variables, whereas significant negative nonzero values represent a negative correlation (<xref rid="B58" ref-type="bibr">58</xref>). Negative correlations are observed when two variables are inversely related to one another; that is, when one variable increases, the other decreases. With these data, as bacterial burden would drop, then the correlate would increase (negative correlation; inverse). A positive correlation would mean that as the bacterial burden increases, so does the correlate to which it is being compared.</p>
                <p>IM-wP-vaccinated rats had strong negative correlations (protective) between serum anti-<italic toggle="yes">B. pertussis</italic> IgG antibodies to both bacterial burden in the lung (<italic toggle="yes">R</italic><sup>2</sup> = −0.97) at day 1 postchallenge and the nasal cavity (<italic toggle="yes">R</italic><sup>2</sup> = −0.84) at day 9 postchallenge (<xref rid="F8" ref-type="fig">Fig. 8A</xref> and <xref rid="F8" ref-type="fig">B</xref>). At day 1 postchallenge, we observed negative correlations (protective) between systemic anti-<italic toggle="yes">B. pertussis</italic> IgM and anti-PT IgG antibodies in IM-aP-vaccinated rats to bacterial burden in the nasal cavity (R<sup>2</sup> = −0.64 and −0.64, respectively). In addition, negative correlations were observed between anti-<italic toggle="yes">B. pertussis</italic> IgM antibodies and bacterial burden in the trachea (<italic toggle="yes">R</italic><sup>2</sup> = −0.72) at day 9 postchallenge (<xref rid="F8" ref-type="fig">Fig. 8C</xref> and <xref rid="F8" ref-type="fig">D</xref>). IM-aP-vaccinated rats also had negative correlations between total cough counts over the course of challenge with IgG and IgM antibodies to <italic toggle="yes">B. pertussis</italic> and PT (<xref rid="F8" ref-type="fig">Fig. 8D</xref>). We expected that i.n. immunization would induce negative correlations between both serum- and mucosa-specific antibodies compared to bacterial burden in the lung, trachea, and nasal cavity at day 1 postchallenge, which is what we observed (<xref rid="F8" ref-type="fig">Fig. 8E</xref>). Lung anti-<italic toggle="yes">B. pertussis</italic> IgA antibodies also negatively correlated with total cough count (<italic toggle="yes">R</italic><sup>2</sup> = −0.74) and bacterial burden (<italic toggle="yes">R</italic><sup>2</sup> = −0.6) in the lung at day 9 postchallenge for IN-aP-vaccinated rats (<xref rid="F8" ref-type="fig">Fig. 8F</xref>). We observed strong negative correlations between serum IgG and mucosal IgA antibody to bacterial burden in the lungs (<italic toggle="yes">R</italic><sup>2</sup> = −0.93 and −0.93, respectively) in OG-aP-vaccinated rats at day 1 postchallenge despite the overall lower serological responses (<xref rid="F8" ref-type="fig">Fig. 8G</xref>). At day 9 postchallenge, there was a negative correlation between serum anti-<italic toggle="yes">B. pertussis</italic> IgG antibodies to bacterial burden in the lungs (<italic toggle="yes">R</italic><sup>2</sup> = −0.81), tracheas (<italic toggle="yes">R</italic><sup>2</sup> = −0.49), and nasal cavities (<italic toggle="yes">R</italic><sup>2</sup> = −0.52) in OG-aP-immunized rats (<xref rid="F8" ref-type="fig">Fig. 8H</xref>). We also noticed that OG-aP vaccinated rats had negative correlations between serum IgG and mucosal IgA antibodies in the lung to total cough count (<italic toggle="yes">R</italic><sup>2</sup> = −0.94 and −0.84) at day 9 postchallenge (<xref rid="F8" ref-type="fig">Fig. 8H</xref>). Positive correlations (nonprotective) were observed between bacterial burden and total inflammatory score in IM-wP-, IM-aP-, and OG-aP-immunized rats (<xref rid="F8" ref-type="fig">Fig. 8A, C,</xref> and <xref rid="F8" ref-type="fig">G</xref>). The bacterial burden also positively correlated with total cough counts at day 9 postchallenge (<xref rid="F8" ref-type="fig">Fig. 8B, D, F,</xref> and <xref rid="F8" ref-type="fig">H</xref>). By utilizing correlograms, strong negative correlations between serum serological responses and bacterial burden were observed in IM-wP- and IM-aP-immunized rats. In addition, our data underscore the idea that both systemic and mucosal antibodies correlate with the observed <italic toggle="yes">B. pertussis</italic> clearance in the respiratory tract and protection from <italic toggle="yes">B. pertussis</italic>-induced cough elicited by IN-aP and OG-aP vaccination, highlighting the observed differences between vaccination routes.</p>
                <fig position="float" id="F8">
                  <label>FIG 8</label>
                  <caption>
                    <p>Systemic and mucosal anti-<italic toggle="yes">B. pertussis</italic> and anti-PT antibodies correlate with observed protection. Correlograms were generated using the observed data for IM-wP (A and B), IM-aP (C and D), IN-aP (E and F), and OG-aP (G and H) immunizations. Program R was used to make correlation graphs from raw data for both day 1 and day 9 postchallenge. <italic toggle="yes">R</italic><sup>2</sup> values were generated when generating the correlograms. Positive correlations are annotated by blue circles, while the negative correlations are annotated by red circles. The size of the circle indicates the strength of the correlation.</p>
                  </caption>
                  <graphic xlink:href="iai.00346-21-f008" position="float"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s3">
              <title>DISCUSSION</title>
              <p>The immunity induced by aP vaccines is relatively short-lived; thus, DTaP/Tdap-vaccinated individuals are still capable of <italic toggle="yes">B. pertussis</italic> transmission (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B59" ref-type="bibr">59</xref>). We have recently reinvestigated the rat model of pertussis to further understand <italic toggle="yes">B. pertussis</italic> pathogenesis from current circulating <italic toggle="yes">B. pertussis</italic> strains (such as CDC isolate D420) (<xref rid="B43" ref-type="bibr">43</xref>). The coughing rat model of pertussis is a tool that can be used to evaluate bacterial burden in the respiratory tract and also evaluate vaccine-induced immunity against cough and respiratory function (<xref rid="B36" ref-type="bibr">36</xref><xref rid="B37" ref-type="bibr">–</xref><xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B60" ref-type="bibr">60</xref>). In our previous study and in the present study, we utilized i.n. challenge to infect rats in order to study immune responses, the bacterial burden, and the coughing phenotype (<xref rid="B61" ref-type="bibr">61</xref>). Here, we evaluated mucosal vaccination with DTaP in the coughing rat model of pertussis. To our knowledge, this study is the first to evaluate both i.n.- and o.g.-administered DTaP in the coughing rat model of pertussis. The data presented here suggest that mucosal immunization protects not only against bacterial burden but also against <italic toggle="yes">B. pertussis</italic>-induced cough, as determined by WBP (<xref rid="F2" ref-type="fig">Fig. 2</xref> and <xref rid="F7" ref-type="fig">7</xref>).</p>
              <p>Vaccine-mediated immunity has been studied in the coughing rat model of pertussis. Utilizing audio tape recorders, Hall et al. illustrated in 1998 that three- and five-component aP vaccines administered subcutaneously could protect against <italic toggle="yes">B. pertussis</italic>-induced cough (<xref rid="B41" ref-type="bibr">41</xref>). In another study, wP immunization administered intraperitoneally also decreased the incidence of cough in rats (<xref rid="B39" ref-type="bibr">39</xref>). Neither study noted protection against bacterial colonization. Here, in the present study, WBP was used to investigate <italic toggle="yes">B. pertussis</italic>-induced cough in IN-aP- and OG-aP-vaccinated rats, as well as to measure the bacterial burden in the respiratory tract. Our data support that mucosal administration of DTaP protects against bacterial burden in the respiratory tract and reduced <italic toggle="yes">B. pertussis</italic>-induced cough (<xref rid="F2" ref-type="fig">Fig. 2</xref> and <xref rid="F7" ref-type="fig">7</xref>). In addition, IN-aP vaccination reduced bronchial constriction in the lung that is elicited by <italic toggle="yes">B. pertussis</italic> infection (<xref rid="F4" ref-type="fig">Fig. 4</xref>). Previous studies evaluating wP and aP vaccines in the rat model of pertussis used one human dose per rat for immunization prior to challenge (<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B41" ref-type="bibr">41</xref>). In an effort to best model an appropriate human-to-rat dose, we utilized a 1/5 human dose to prime and boost based on the relative sizes of rats compared to mice. We have reported that a 1/40 human dose is protective in mice, and rats are roughly 10× the weight of mice (<xref rid="B62" ref-type="bibr">62</xref>). One caveat of this study is that we did not evaluate other human-to-rat titrations of aP. Identification of a minimal protective rat dose would allow for the investigation of vaccine efficacy of new potential antigens/adjuvants in this model (<xref rid="B62" ref-type="bibr">62</xref>).</p>
              <p>Mucosal immunization has been of particular interest in the pertussis field. We and others have recently evaluated i.n. immunization of DTaP in <italic toggle="yes">B. pertussis</italic>-challenged mice (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B63" ref-type="bibr">63</xref><xref rid="B64" ref-type="bibr">–</xref><xref rid="B65" ref-type="bibr">65</xref>). Intranasally DTaP-vaccinated mice were protected against <italic toggle="yes">B. pertussis</italic> challenge and also generated both systemic and mucosal antibodies (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>). Live attenuated strain BPZE1 administered i.n. was protective against <italic toggle="yes">B. pertussis</italic> challenge in mice and baboons and is currently in phase 2 of clinical studies (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>). BPZE1 immunization induces both anti-<italic toggle="yes">B. pertussis</italic> IgG and IgA antibodies systemically and leads to an increase in resident memory T cells in the lung (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B35" ref-type="bibr">35</xref>). Oral immunization has also been investigated as a possible vaccination strategy against pertussis. Oral immunization of heat-inactivated <italic toggle="yes">B. pertussis</italic> not only protected newborns against <italic toggle="yes">B. pertussis</italic> challenge but also generated serum and saliva antibody titers (<xref rid="B30" ref-type="bibr">30</xref>). Recombinant technologies have led to the development of live attenuated <named-content content-type="genus-species">Salmonella</named-content> strains presenting <italic toggle="yes">B. pertussis</italic> antigens (<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B69" ref-type="bibr">69</xref>). Oral immunization of the <named-content content-type="genus-species">Salmonella</named-content> Typhimurium <italic toggle="yes">aro</italic> vaccine strain harboring the gene for PRN resulted in reduced bacterial colonization in the lung following <italic toggle="yes">B. pertussis</italic> challenge (<xref rid="B68" ref-type="bibr">68</xref>). A <named-content content-type="genus-species">Salmonella dublin</named-content>
<italic toggle="yes">aroA</italic> mutant expressing the gene for FHA was also orally administered as a vaccine in mice (<xref rid="B69" ref-type="bibr">69</xref>). Vaccination with this strain induced IgG and IgA antibody titers to FHA in sera and in the gut (<xref rid="B69" ref-type="bibr">69</xref>). The present study shows that mucosal immunization induced not only systemic anti-<italic toggle="yes">B. pertussis</italic> IgG but also anti-<italic toggle="yes">B. pertussis</italic> IgA antibodies that likely play role in clearance at the mucosa (<xref rid="F4" ref-type="fig">Fig. 4</xref>, <xref rid="F5" ref-type="fig">5</xref>, and <xref rid="F7" ref-type="fig">7</xref>).</p>
              <p>CoP is defined as the immune response that is statistically accountable for the observed protection (<xref rid="B70" ref-type="bibr">70</xref>). While no CoP has yet to be fully agreed upon against pertussis in humans, anti-PT IgG levels of &gt;5 IU/ml are associated with protection in humans (<xref rid="B71" ref-type="bibr">71</xref>). In mice, i.n. administration of DTaP induced anti-<italic toggle="yes">B. pertussis</italic>, anti-FHA, and anti-PT IgG antibodies, while wP vaccination induced serum anti-<italic toggle="yes">B. pertussis</italic> IgG antibodies that correlated with protection against <italic toggle="yes">B. pertussis</italic> (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B57" ref-type="bibr">57</xref>). Here, in this study, we generated correlograms between all vaccinated groups to identify correlations between variables in the coughing rat model of pertussis, which has yet to be established (<xref rid="F8" ref-type="fig">Fig. 8</xref>). Our results indicate that the bacterial burden in the lung, trachea, and nasal cavity negatively correlates with systemic anti-<italic toggle="yes">B. pertussis</italic> and -PT IgM and anti-<italic toggle="yes">B. pertussis</italic> IgG antibodies in IM-wP- and IM-aP-immunized rats, while systemic and mucosal antibodies correlate with bacterial clearance in IN-aP- and OG-aP-vaccinated rats (<xref rid="F8" ref-type="fig">Fig. 8</xref>). Antibodies generated after immunization also negatively correlated with a decrease in total cough counts in vaccinated rats (<xref rid="F8" ref-type="fig">Fig. 8</xref>). These results suggest that the increase in systemic and mucosal antibodies induced from i.n. and o.g. vaccinations correlates with protection against a <italic toggle="yes">B. pertussis</italic> burden in the respiratory tract and against <italic toggle="yes">B. pertussis</italic>-induced cough. It is important to note that OG-aP-immunized rats did not generate significant serum antibody titers to the whole bacterium until day 9 postchallenge (<xref rid="F4" ref-type="fig">Fig. 4B</xref>). Also, two OG-aP-immunized rats had an increase in anti-PT IgG antibody titers in the serum and anti-<italic toggle="yes">B. pertussis</italic> IgA antibodies in the lung (<xref rid="F4" ref-type="fig">Fig. 4D</xref> and <xref rid="F5" ref-type="fig">5A</xref>). We did, however, detect antigen-specific B cells in the bone marrow, and three of the four rats had low levels of IgA in the lungs in OG-aP-immunized rats (see Fig. S3). We hypothesize that this could be because limited amount of vaccine that successfully travels to the gut-associated lymphoid tissue (GALT) for the generation of an immune response. Oral vaccines have to travel through increased pH in the stomach, while limited absorption and availability for antigen recognition also occur in the gastrointestinal tract (<xref rid="B72" ref-type="bibr">72</xref>). Increases in the dose or the number of doses or changes to the delivery of the vaccine in an encased vehicle are potential methods to increase orally vaccinated immune responses. Targeting of vaccine to intestinal M cells for antigen presentation has also been shown to increase oral vaccine efficacy (<xref rid="B73" ref-type="bibr">73</xref>). Though we did not study new adjuvants here, we hypothesize that adjuvants can aid in stimulating a protective mucosal immune response. These approaches could all potentially increase the efficacy observed through oral vaccination of aP. Furthermore, to deliver the vaccine to the gut, one could envision novel delivery mechanisms such as gelatin-coated chewables similar to the gummy vitamins that are now popular. One caveat that should be mentioned is that we did not investigate the T-cell responses (Th1/Th2/Th17/Trm/Tem) in rats, but future studies will incorporate this into the study design. Furthermore, we did not observe the vast changes in cytokine responses in this model that have been observed in mouse and baboon models of pertussis, such as IL-6 and IL-17.</p>
              <p>We have proposed a summary for mechanism for oral vaccination of aP (see Fig. S9). Generation of antibodies relies on both antigen presentation and antigen recognition. Based on our serological analysis, OG-aP-immunized rats developed measurable anti-<italic toggle="yes">B. pertussis</italic> IgG antibodies at day 9 postchallenge (<xref rid="F4" ref-type="fig">Fig. 4B</xref>). In addition, two of the four OG-aP-immunized rats developed both anti-PT IgG and anti-<italic toggle="yes">B. pertussis</italic> IgA antibodies in the serum and lung, respectively (<xref rid="F4" ref-type="fig">Fig. 4D</xref> and <xref rid="F5" ref-type="fig">5A</xref>). Detection of both IgG and IgA antibodies suggest both germinal center reactions and <italic toggle="yes">B. pertussis</italic>-specific humoral immunity. ELISpot data identified the presence <italic toggle="yes">B. pertussis</italic>-specific B cells in the bone marrow in OG-aP-vaccinated rats, and we hypothesize that these B cells home from the lymph to the marrow awaiting recall (see Fig. S3). Further studies are needed not only to confirm germinal center reactions in the Peyer’s patches but also to determine whether direct class switching and terminal differentiation occurs.</p>
              <p>In summary, mucosal vaccination not only protected against bacterial burden in the respiratory tract of challenged rats but also protected against <italic toggle="yes">B. pertussis</italic>-induced cough and respiratory distress, as measured by WBP (<xref rid="F2" ref-type="fig">Fig. 2</xref>, <xref rid="F3" ref-type="fig">3</xref>, and <xref rid="F7" ref-type="fig">7</xref>). It is critical that “next-generation pertussis vaccines” protect against bacterial colonization in the lung, nasal cavity, and trachea, since disease manifestations are dependent on bacterial colonization of the lung and trachea, mediated by FHA and fimbriae (<xref rid="B74" ref-type="bibr">74</xref>, <xref rid="B75" ref-type="bibr">75</xref>). The coughing rat model of pertussis can be used as a tool to truly evaluate not only bacterial burden but also other clinical manifestations of pertussis, such as cough and respiratory distress, that have not been characterized in the mouse model of pertussis. Interestingly, we have recently performed pilot studies with aerosolization of <italic toggle="yes">B. pertussis</italic>, and we have confirmed that aerosol delivery can result in a similar bacterial burden at day 1 postchallenge. We expect to further investigate the aerosol challenge model with rats as well.</p>
              <p>We observed that both i.n.- and o.g.-immunized rats generated anti-<italic toggle="yes">B. pertussis</italic>-specific IgG antibodies in the serum, while i.n. vaccination also generated significant anti-<italic toggle="yes">B. pertussis</italic> IgA antibody titers in the nasal cavity after challenge (<xref rid="F4" ref-type="fig">Fig. 4</xref> and <xref rid="F5" ref-type="fig">5</xref>). IN-aP- and OG-aP-immunized rats were protected against neutrophilic infiltration in the lung (<xref rid="F6" ref-type="fig">Fig. 6</xref>). Further investigation into mononuclear involvement via i.n. vaccination is needed to delineate potential beneficial or undesired involvement in this model. Histological analysis prior to vaccination could also identify whether the observed mononuclear infiltrates are induced via i.n. vaccination solely. To fully detail the most effective route of immunization, further studies are needed to determine whether mucosal immunization addresses the problem of waning vaccine immunity. Future studies testing additional adjuvants and vaccine doses would also improve mucosal vaccine formulations. Overall, our data continue to support the potential of a mucosal vaccination against <italic toggle="yes">B. pertussis.</italic></p>
              <p>More studies are needed to fully characterize the immune response generated following IN-aP and OG-aP vaccination in rats, as well as vaccine-mediated immunity from vaccination in the coughing rat model of pertussis. T-cell immune responses that have been shown to play a role in natural and vaccine-mediated immunity against pertussis have yet to be evaluated in the coughing rat model of pertussis due to the limited availability of resources to adequately measure T-cell responses. Vaccine-mediated memory has yet to be evaluated in the coughing rat model of pertussis. Additional research is needed to critically assess vaccine mediated memory, since it is essential that the next generation of pertussis vaccines induces longer-lasting memory than do current vaccines. Future work is also needed to evaluate mucosal immunization against current circulating strains of <italic toggle="yes">B. pertussis</italic> since current strains are genetically divergent from strains of the past, with the goal of making the most efficacious vaccine against <italic toggle="yes">B. pertussis</italic>.</p>
            </sec>
            <sec sec-type="materials|methods" id="s4">
              <title>MATERIALS AND METHODS</title>
              <sec id="s4-1">
                <title>Vaccine composition and administration.</title>
                <p>INFANRIX (GSK, catalog no. 58160-810-11) acellular pertussis human vaccine (DTaP) and the National Institute for Biological Standards and Control WHO whole-cell pertussis vaccine (NIBSC code 94/532) were used for this study. Vaccines were diluted with endotoxin-free Dulbecco PBS (Thermo Fisher Scientific, catalog no. TMS012A) to a concentration of 1/5 the human dose. Vaccines were diluted and administered no more than 1 h from composition. The first dose of vaccine was administered to 3-week-old (50 g) female Sprague-Dawley rats (Charles River, catalog no. 001CD). When the animals were 6 weeks old, a booster vaccine of the same dose was administered, followed by <italic toggle="yes">B. pertussis</italic> challenge at 8 weeks of age. Intramuscular (i.m.)-vaccinated rats received 100 μl in the right thigh muscle of the hind limb. Intranasal (i.n.)-immunized rats were first anesthetized with isoflurane until breathing was minimal. Rats then received 50 μl of vaccine in each nostril for a 100-μl dose. Oral gavage (o.g.)-vaccinated rats received a 100-μl dose delivered via a curved 18-gauge feeding needle (Fisher Scientific, catalog no. NC9349775). The MVC control group received 100 μl of the same endotoxin-free PBS used to dilute the vaccines in the right thigh muscles of the hind limb. At 1 week postprime, 2 weeks postprime, and 1 week postboost, blood was collected via saphenous blood draws for serological analysis. Then, 5-mm animal lancets (Fisher Scientific, catalog no. NC9891620) were used for the blood draw. Blood was collected in capillary tubes (Fisher Scientific, catalog no. NC9059691) for centrifugation. Blood was spun at 15,000 × <italic toggle="yes">g</italic> for 3 min, and serum samples were collected and stored at −80°C until analysis.</p>
              </sec>
              <sec id="s4-2">
                <title><italic toggle="yes">Bordetella pertussis</italic> strains and growth conditions.</title>
                <p><italic toggle="yes">B. pertussis</italic> strain D420 (GenBank accession no. <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/LN849008.1" ext-link-type="uri" assigning-authority="insdc">LN849008.1</ext-link>) was cultured on Bordet-Gengou (BG) agar (Remel, catalog no. R45232) supplemented with 15% defibrinated sheep blood (Hemostat Laboratories, catalog no. DSB500) (<xref rid="B1" ref-type="bibr">1</xref>). Bacteria cultured in BG plates were incubated for 48 h at 36°C. Using polyester swabs (Puritan, catalog no. 22-029-574), we transferred <italic toggle="yes">B. pertussis</italic> into 20 ml of Stainer-Scholte liquid media (SSM) in new 125-ml flasks (Thermo Fisher Scientific, catalog no. FB500125) (<xref rid="B76" ref-type="bibr">76</xref>). Bacterial cultures were allowed to grow at 36<sup>°</sup>C for 24 h inside a shaking incubator at 180 rpm.</p>
              </sec>
              <sec id="s4-3">
                <title>Intranasal challenge.</title>
                <p>Vaccinated 8-week-old ∼200-g female Sprague-Dawley rats were then challenged. <italic toggle="yes">B. pertussis</italic> was grown as illustrated above. Rats were anesthetized with ketamine and xylazine at 50 to 100 and 5 to 10 mg/kg, respectively, and challenged with 10<sup>8</sup> CFU in 100 μl i.n., 50 μl in each nostril. The body weight of each rat was recorded before bacterial challenge, and body weights were taken posteuthanasia to calculate the percent weight change. At days 1 and 9 postchallenge, the rats were euthanized. Upon euthanasia, blood was collected via cardiac puncture and transferred into EDTA (BD, catalog no. 365974) and serum separation (BD, catalog no. 026897) tubes. After cardiac puncture, 250 μl of blood was collected into EDTA tubes for flow cytometry and ProCyte (IDEXX) hematology analysis, while the remaining blood was collected in serum separation tubes to isolate the serum via centrifugation (15,000 × <italic toggle="yes">g</italic> for 3 min) and then used for serological and cytokine analysis. To determine the bacterial burden in the respiratory tract, the lungs and tracheas were excised separately and homogenized. Lung weights were recorded following excision before homogenization. The lungs were then collected in gentleMACS C-tubes (Miltenyi Biotec, catalog no. 130-096-334) in 2 ml of PBS and homogenized using a Miltenyi Biotec tissue dissociator (catalog no. 130-095-927). A polytron homogenizer was used to homogenize the trachea in 1 ml of PBS. The bacterial burden in the nares was determined by flushing 2 ml of sterile 1× PBS through the nares, and samples were collected for serial dilution and plating. Serial dilutions of the homogenates and nasal collection were plated on BG plates supplemented with ceftibuten (Sigma-Aldrich, catalog no. SML0037) at 10 μg/ml.</p>
              </sec>
              <sec id="s4-4">
                <title>Serological analysis.</title>
                <p>ELISAs were performed to measure the antibody titers of vaccinated and infected rats. <italic toggle="yes">B. pertussis</italic>-specific whole-bacterium ELISA plates were coated with 50 μl of 10<sup>8</sup> CFU of <italic toggle="yes">B. pertussis</italic> grown as described above for infection. Antigen-specific antibody titers to PT (List Biological Laboratories, catalog no. 180) were measured by coating ELISA plates with 50 μl of antigen per well. Antigen-coated plates incubated overnight at 4°C. After incubation, the plates were washed with 1× PBS–Tween 20 and blocked with 5% skimmed milk for 2 h at 37°C. After blocking, ELISA plates were washed, and serum samples from the saphenous blood draws and blood collected from cardiac puncture posteuthanasia were serially diluted down the ELISA plate, followed by incubation for 2 h at 37°C. To measure respiratory IgA antibody titers in the lungs and nasal lavages, lung homogenate supernatant and nasal lavage were added, followed by incubation for 2 h at 37°C. After incubation, the ELISA plates were washed as described above, and 100 μl of secondary goat anti-rat IgG (Southern Biotech, catalog no. 3030-04), goat anti-rat IgM (Southern Biotech, catalog no. 3020-04), or goat anti-rat IgA (MyBioSource, catalog no. MBS539212) was added to the plates at a dilution of 1:2,000 in PBS–5% milk, followed by incubation for 1 h at 37°C. The plates were then washed again, 100 μl of <italic toggle="yes">p</italic>-nitrophenyl phosphate substate (Thermo Scientific, catalog no. 37620) was added, and the plate was developed for 30 min at room temperature. After development, the colorimetric signal of the ELISA plate at <italic toggle="yes">A</italic><sub>450</sub> was measured by using a BioTek Synergy H1 microplate reader. Antibody titers were considered positive if values were higher than the baseline value. The baseline value for each sample was set as double the average value of the blank, to which no serum, lung supernatant, or nasal lavage had been added. The limit of detection was set at 50, and any samples with a titer value less than that were set to 50.</p>
              </sec>
              <sec id="s4-5">
                <title>ELISpot assay.</title>
                <p>An ELISpot assay (ImmunoSpot, catalog no. mTgG-SCE-1M/2) was used to analyze antigen-specific B cells in the bone marrow. The right hind femur of each rat was removed, placed in Dulbecco modified Eagle medium, and frozen at −80°C until analysis. The bones were then thawed in a water bath at 37°C, immediately transferred to spin tubes, and spun at 1,000 × <italic toggle="yes">g</italic> for 3 min to collect the bone marrow. The bone marrow was passed through a 70-μm filter to create a single-cell suspension. Cells were centrifuged at 350 × <italic toggle="yes">g</italic> for 5 min, and the cell pellet was resuspended in CTL test B media (ImmunoSpot). D420 was cultured as described above and coated the 96-well ELISpot plate, as described above for the ELISA. The plate was incubated overnight at 4°C and then washed with 1× PBS before cells were added. Three serial dilutions of cells (1.25 × 10<sup>6</sup>, 3.13 × 10<sup>5</sup>, and 1.56 × 10<sup>5</sup>) were added per well, followed by incubation at 37°C overnight. Rabbit anti-rat IgG antibody (Abcam, catalog no. ab6733) was used to replace the anti-murine IgG detection antibody that was provided with the kit. The rest of the protocol was followed according to the manufacturer’s instructions. The ELISpot plates were imaged and analyzed using an ImmunoSpot S6 Entry analyzer and CTL software.</p>
              </sec>
              <sec id="s4-6">
                <title>Analysis of cough and bronchiole restriction using WBP.</title>
                <p>Buxco FinePointe WBP (DSI) was used to quantify respiratory function during infection. Every day following <italic toggle="yes">B. pertussis</italic> challenge and 1 day before challenge (5:00 p.m.), rat respiratory profiles and coughs were measured. FinePointe software was used to record respiratory parameters. A 5-min acclimation period was used before measuring the coughs and other respiratory parameters. After acclimation, the respiratory profile was recorded for 15 min for each rat. Coughs were counted over 15 min. The enhanced pause (PenH) was calculated as follows by measuring the peak expiratory height (PEF) and peak inspiratory height (PIF) and the time it takes for the rat to breathe each breath: PenH = (PEF/PIF) × [(Te/Tr) – 1], which represents bronchiole restriction during breathing. An increase in PenH indicates an increase in pulmonary distress. Coughs were counted based on box flow changes of the subject with classical cough-like waveforms. Patented fuzzy logic criteria was used to detect and count coughs (<xref rid="B77" ref-type="bibr">77</xref>). Each cough in a multicough event was counted individually. The frequency (F), tidal volume (TVb), pause (PAU), minute volume (MVb), inspiratory time (Ti), and expiratory time (Te) were also recorded and analyzed over the course of infection.</p>
              </sec>
              <sec id="s4-7">
                <title>Histological assessment of the lung.</title>
                <p>The left lobe of the lung was used for histological assessment. After excision of the left lobe, the sectioned portion was fixed in 10% formalin 48 h at 26°C. After fixation, samples were embedded in paraffin and stained with H&amp;E by the WVU Pathology Department. Stained samples were used to characterize and score inflammation of the lung. All scorings were done by a board-certified pathologist (iHisto). Individual scores were determined using a standard qualitative scoring criterion: 0, none; 1, minimal (rare); 2, mild (slight); 3, moderate; 4, marked; and 5, severe. The presence of neutrophils in the parenchyma, blood vessels, and airway was used to score acute inflammation, and chronic inflammation was characterized by mononuclear infiltrates of the parenchyma, blood vessels, and airway. All examination and scoring were done with no knowledge of the groups.</p>
              </sec>
              <sec id="s4-8">
                <title>ProCyte analysis of blood.</title>
                <p>Blood from the EDTA tubes was used to analyze white blood cell, neutrophil, and lymphocyte counts. Samples (25 to 50 μl) of blood were drawn from the EDTA tubes and analyzed by the ProCyte. After ProCyte analysis, the rest of the blood was used for flow cytometry analysis.</p>
              </sec>
              <sec id="s4-9">
                <title>Flow cytometry analysis.</title>
                <p>Blood samples were lysed with 1× PharmLyse buffer (BD Biosciences, catalog no. 555899) for 20 min at room temperature. Blood samples were vortexed periodically during the 20-min incubation. After lysis, the cells were resuspended in RPMI–10% FBS to neutralize the lysis buffer and centrifuged five times at 1,000 × <italic toggle="yes">g</italic>. The cells were then washed with RPMI–10% FBS again. The cells were next resuspended in 1% FBS–PBS–5 mM EDTA. Blood samples were blocked with anti-CD32 (BD Pharmingen, catalog no. 550270) antibody for 15 min at 4°C. After blocking, the cells were labeled with CD45-Alexa Fluor 700 (BioLegend, catalog no. 202218), CD161-APC (BioLegend, catalog no. 205606), CD45R-PE-Cy7 (eBioscience, catalog no. 25-0460-82), His48-FITC (eBioscience, catalog no. 11-0570-82), CD43-PE (BioLegend, catalog no. 202812), or CD3-VioGreen (Miltenyi Biotec, catalog no. 130-119-125) (<xref rid="B78" ref-type="bibr">78</xref>). The samples were then incubated for 1 h at 4°C in the dark. To prepare the lung samples for flow cytometry, the lung homogenate was filtered through a 70-μm cell strainer (BioDesign Cell MicroSives, catalog no. N70R). The suspension was centrifuged at 1,000 × <italic toggle="yes">g</italic> for 5 min. The pellet was resuspended in PharmLyse buffer, followed by incubation at 37°C for 2 min. After incubation, the cells were centrifuged at 1,000 × <italic toggle="yes">g</italic> for 5 min, the lysis buffer was removed, and the cells were blocked and labeled with antibody, as described for blood samples. Both blood and lung samples were centrifuged at 1,000 × <italic toggle="yes">g</italic> for 5 min, and the pellets were resuspended in 0.4% paraformaldehyde and stored overnight at 4°C. The samples were washed with 1× PBS–5mM EDTA–1% FBS and resuspended in 1× PBS–5 mM EDTA–1% FBS for analysis. Cell samples were analyzed on a LSR Fortessa, and samples were gated and analyzed using FlowJo v10.</p>
              </sec>
              <sec id="s4-10">
                <title>Cytokine analysis.</title>
                <p>Lung homogenates were centrifuged at 19,000 × <italic toggle="yes">g</italic> for 4 min, and the resulting supernatant was removed and stored at −80°C until further analysis. Lung supernatants and serum cytokines were measured using a ProcartaPlex multiplex immunoassay kit (Complete 14-Plex Rat ProcartaPlex panel; Thermo Fisher Scientific, catalog no. EPX140-30120-901) according to the manufacturer’s instructions. Cytokines with bead counts of &lt;35 were invalidated.</p>
              </sec>
              <sec id="s4-11">
                <title>Generation of correlograms.</title>
                <p>Correlograms were created using R Studio software (version 1.4.1106). Pearson correlation coefficients were calculated between each set of variables listed in the master table and then illustrated in a representative plot for each vaccine route and time point.</p>
              </sec>
              <sec id="s4-12">
                <title>Statistical analysis.</title>
                <p>GraphPad Prism 7 was used to analyze the data. The minimum biological replicates for the challenge studies were three for the MVC control group and four rats per vaccinated group. For statistical comparisons between vaccinated groups and the MVC control group over the entire course of the infection, two-way analysis of variance (ANOVA) was used with Dunnett’s <italic toggle="yes">post hoc</italic> test. One-way ANOVA was used for comparison between vaccinated groups and MVC controls for an individual day or time point with Dunnett’s <italic toggle="yes">post hoc</italic> test. A Kruskal-Wallis test with Dunnett’s <italic toggle="yes">post hoc</italic> test was used for comparisons between groups for mucosal IgA comparisons. A ROUT test was used to identify any potential outliers during cytokine analysis of the lung.</p>
              </sec>
              <sec id="s4-13">
                <title>Ethics statement.</title>
                <p>This challenge studies were performed in accordance with West Virginia University Institutional Animal Care and Use Committee (IACUC) protocol 1811019148.6. All research was approved by West Virginia University Institutional Biosafety Committee protocol 17-11-01.</p>
              </sec>
              <sec id="s4-14">
                <title>Data availability.</title>
                <p>Data requests for figures provided can be addressed to the corresponding author.</p>
              </sec>
            </sec>
          </body>
          <back>
            <ack>
              <title>ACKNOWLEDGMENTS</title>
              <p>The work performed in this project was supported by the Vaccine Development Center at WVU-HSC through a Research Challenge Grant (HEPC.dsr.18.6) from the Division of Science and Research, WV Higher Education Policy Commission. The project was also supported by NIH R01AI137155 (F.H.D.). Part of the project was also supported by CDC Contract Broad Agency Announcement (BAA) 75D301-19-R-67835. Flow cytometry experiments were performed in the West Virginia University Flow Cytometry Core Facility, which is supported by the National Institutes of Health (equipment grant S10OD016165) and the Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grants P30GM103488 (CoBRE) and P20GM103434 (INBRE).</p>
              <p>J.M.H. and G.J.B. performed vaccination and bacterial challenge. J.M.H. and G.J.B. monitored rats by using whole-body plethysmography. All authors participated in the animal experiments. J.M.H. and T.Y.W. prepared flow cytometry samples. J.M.H. and M.A.W. performed cytokine analysis. J.M.H. performed ELISA assays. M.A.D. constructed correlograms. J.M.H., M.B., and F.H.D. contributed to experimental design. J.M.H. wrote manuscript, with editing and reviews from all authors.</p>
              <p>We thank Jacqueline Karakiozis, Brice Hickey, and Mary Tomago-Chesney (Pathology/Histology Core Facility) for the preparation of lung slides and staining lung slides with H&amp;E for scoring analysis. We also thank Kathleen Brundage (WVU Flow Cytometry and Single Cell Core Facility) for assisting in flow cytometry and equipment instruction.</p>
              <p>Figures S1 and S8 were created with BioRender.com.</p>
            </ack>
            <fn-group>
              <fn fn-type="supplementary-material">
                <p>Supplemental material is available online only.</p>
                <p>
                  <supplementary-material id="SuF1" position="float" content-type="local-data">
                    <object-id pub-id-type="doi">10.1128/IAI.00346-21.1</object-id>
                    <label>Supplemental file 1</label>
                    <caption>
                      <p>Supplemental material. Download <inline-supplementary-material id="SF1" xlink:href="iai.00346-21-s0001.pdf" content-type="local-data">iai.00346-21-s0001.pdf, PDF file, 1.0 MB</inline-supplementary-material></p>
                    </caption>
                  </supplementary-material>
                  <supplementary-material id="SuF2" position="float" content-type="local-data">
                    <object-id pub-id-type="doi">10.1128/IAI.00346-21.2</object-id>
                    <label>Supplemental file 2</label>
                    <caption>
                      <p>Supplemental material. Download <inline-supplementary-material id="SF2" xlink:href="iai.00346-21-s0002.xlsx" content-type="local-data">iai.00346-21-s0002.xlsx, XLSX file, 0.05 MB</inline-supplementary-material></p>
                    </caption>
                  </supplementary-material>
                </p>
              </fn>
            </fn-group>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="B1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bordet</surname><given-names>J</given-names></string-name>, <string-name><surname>Gengou</surname><given-names>O</given-names></string-name></person-group>. <year>1906</year>. <article-title>Le microbe de la coqueluche</article-title>. <source>Les Ann Inst Pasteur</source><volume>20</volume>:<fpage>731</fpage>–<lpage>741</lpage>.</mixed-citation>
              </ref>
              <ref id="B2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mattoo</surname><given-names>S</given-names></string-name>, <string-name><surname>Cherry</surname><given-names>JD</given-names></string-name></person-group>. <year>2005</year>. <article-title>Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to <italic toggle="yes">Bordetella pertussis</italic> and other <italic toggle="yes">Bordetella</italic> subspecies</article-title>. <source>Clin Microbiol Rev</source><volume>18</volume>:<fpage>326</fpage>–<lpage>382</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.18.2.326-382.2005</pub-id>.<pub-id pub-id-type="pmid">15831828</pub-id></mixed-citation>
              </ref>
              <ref id="B3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Melvin</surname><given-names>JA</given-names></string-name>, <string-name><surname>Scheller</surname><given-names>EV</given-names></string-name>, <string-name><surname>Miller</surname><given-names>JF</given-names></string-name>, <string-name><surname>Cotter</surname><given-names>PA</given-names></string-name></person-group>. <year>2014</year>. <article-title><italic toggle="yes">Bordetella pertussis</italic> pathogenesis: current and future challenges</article-title>. <source>Nat Rev Microbiol</source><volume>12</volume>:<fpage>274</fpage>–<lpage>288</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro3235</pub-id>.<pub-id pub-id-type="pmid">24608338</pub-id></mixed-citation>
              </ref>
              <ref id="B4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kapil</surname><given-names>P</given-names></string-name>, <string-name><surname>Merkel</surname><given-names>TJ</given-names></string-name></person-group>. <year>2019</year>. <article-title>Pertussis vaccines and protective immunity</article-title>. <source>Curr Opin Immunol</source><volume>59</volume>:<fpage>72</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/j.coi.2019.03.006</pub-id>.<pub-id pub-id-type="pmid">31078081</pub-id></mixed-citation>
              </ref>
              <ref id="B5">
                <label>5</label>
                <mixed-citation publication-type="book"><collab>CDC</collab>. <year>2020</year>. <article-title>Immunology and vaccine-preventable diseases—pink book—pertussis</article-title>. <publisher-name>Centers for Disease Control and Prevention</publisher-name>, <publisher-loc>Atlanta, GA</publisher-loc>.</mixed-citation>
              </ref>
              <ref id="B6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pittman</surname><given-names>M</given-names></string-name></person-group>. <year>1991</year>. <article-title>History of the development of pertussis vaccine</article-title>. <source>Dev Biol Stand</source><volume>73</volume>:<fpage>13</fpage>–<lpage>29</lpage>.<pub-id pub-id-type="pmid">1778306</pub-id></mixed-citation>
              </ref>
              <ref id="B7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Elam-Evans</surname><given-names>H</given-names></string-name>, <string-name><surname>Yankey</surname><given-names>LD</given-names></string-name>, <string-name><surname>Singleton</surname><given-names>D</given-names></string-name>, <string-name><surname>Kang</surname><given-names>JA</given-names></string-name>, <string-name><surname>Ha</surname><given-names>Y</given-names></string-name></person-group>. <year>2017</year>. <article-title>Vaccination coverage among children aged 19–35 months—United States, 2017</article-title>. <source>MMWR Morb Mortal Wkly Rep</source><volume>2018</volume>:<fpage>1123</fpage>–<lpage>1128</lpage>.</mixed-citation>
              </ref>
              <ref id="B8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yeung</surname><given-names>KHT</given-names></string-name>, <string-name><surname>Duclos</surname><given-names>P</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>EAS</given-names></string-name>, <string-name><surname>Hutubessy</surname><given-names>RCW</given-names></string-name></person-group>. <year>2017</year>. <article-title>An update of the global burden of pertussis in children younger than 5 years: a modelling study</article-title>. <source>Lancet Infect Dis</source><volume>17</volume>:<fpage>974</fpage>–<lpage>980</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(17)30390-0</pub-id>.<pub-id pub-id-type="pmid">28623146</pub-id></mixed-citation>
              </ref>
              <ref id="B9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Klein</surname><given-names>NP</given-names></string-name>, <string-name><surname>Bartlett</surname><given-names>J</given-names></string-name>, <string-name><surname>Fireman</surname><given-names>B</given-names></string-name>, <string-name><surname>Baxter</surname><given-names>R</given-names></string-name></person-group>. <year>2016</year>. <article-title>Waning Tdap effectiveness in adolescents</article-title>. <source>Pediatrics</source><volume>137</volume>:<elocation-id>e20153326</elocation-id>. <pub-id pub-id-type="doi">10.1542/peds.2015-3326</pub-id>.<pub-id pub-id-type="pmid">26908667</pub-id></mixed-citation>
              </ref>
              <ref id="B10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Klein</surname><given-names>NP</given-names></string-name>, <string-name><surname>Bartlett</surname><given-names>J</given-names></string-name>, <string-name><surname>Rowhani-Rahbar</surname><given-names>A</given-names></string-name>, <string-name><surname>Fireman</surname><given-names>B</given-names></string-name>, <string-name><surname>Baxter</surname><given-names>R</given-names></string-name></person-group>. <year>2012</year>. <article-title>Waning protection after fifth dose of acellular pertussis vaccine in children</article-title>. <source>N Engl J Med</source><volume>367</volume>:<fpage>1012</fpage>–<lpage>1019</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1200850</pub-id>.<pub-id pub-id-type="pmid">22970945</pub-id></mixed-citation>
              </ref>
              <ref id="B11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Klein</surname><given-names>NP</given-names></string-name>, <string-name><surname>Bartlett</surname><given-names>J</given-names></string-name>, <string-name><surname>Fireman</surname><given-names>B</given-names></string-name>, <string-name><surname>Rowhani-Rahbar</surname><given-names>A</given-names></string-name>, <string-name><surname>Baxter</surname><given-names>R</given-names></string-name></person-group>. <year>2013</year>. <article-title>Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers</article-title>. <source>Pediatrics</source><volume>131</volume>:<fpage>e1716</fpage>–<lpage>e1722</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2012-3836</pub-id>.<pub-id pub-id-type="pmid">23690518</pub-id></mixed-citation>
              </ref>
              <ref id="B12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Althouse</surname><given-names>BM</given-names></string-name>, <string-name><surname>Scarpino</surname><given-names>SV</given-names></string-name></person-group>. <year>2015</year>. <article-title>Asymptomatic transmission and the resurgence of <italic toggle="yes">Bordetella pertussis</italic></article-title>. <source>BMC Med</source><volume>13</volume>:<fpage>146</fpage>. <pub-id pub-id-type="doi">10.1186/s12916-015-0382-8</pub-id>.<pub-id pub-id-type="pmid">26103968</pub-id></mixed-citation>
              </ref>
              <ref id="B13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Templeton</surname><given-names>KE</given-names></string-name>, <string-name><surname>Scheltinga</surname><given-names>SA</given-names></string-name>, <string-name><surname>van der Zee</surname><given-names>A</given-names></string-name>, <string-name><surname>Diederen</surname><given-names>BMW</given-names></string-name>, <string-name><surname>van Kruijssen</surname><given-names>AM</given-names></string-name>, <string-name><surname>Goossens</surname><given-names>H</given-names></string-name>, <string-name><surname>Kuijper</surname><given-names>E</given-names></string-name>, <string-name><surname>Claas</surname><given-names>ECJ</given-names></string-name></person-group>. <year>2003</year>. <article-title>Evaluation of real-time PCR for detection of and discrimination between <italic toggle="yes">Bordetella pertussis</italic>, <italic toggle="yes">Bordetella parapertussis</italic>, and <italic toggle="yes">Bordetella holmesii</italic> for clinical diagnosis</article-title>. <source>J Clin Microbiol</source><volume>41</volume>:<fpage>4121</fpage>–<lpage>4126</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.41.9.4121-4126.2003</pub-id>.<pub-id pub-id-type="pmid">12958235</pub-id></mixed-citation>
              </ref>
              <ref id="B14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Warfel</surname><given-names>JM</given-names></string-name>, <string-name><surname>Zimmerman</surname><given-names>LI</given-names></string-name>, <string-name><surname>Merkel</surname><given-names>TJ</given-names></string-name></person-group>. <year>2014</year>. <article-title>Acellular pertussis vaccines protect against disease butfail to prevent infection and transmission in a nonhuman primate model</article-title>. <source>Proc Natl Acad Sci USA</source><volume>111</volume>:<fpage>787</fpage>–<lpage>792</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1314688110</pub-id>.<pub-id pub-id-type="pmid">24277828</pub-id></mixed-citation>
              </ref>
              <ref id="B15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wendelboe</surname><given-names>AM</given-names></string-name>, <string-name><surname>Van Rie</surname><given-names>A</given-names></string-name>, <string-name><surname>Salmaso</surname><given-names>S</given-names></string-name>, <string-name><surname>Englund</surname><given-names>JA</given-names></string-name></person-group>. <year>2005</year>. <article-title>Duration of immunity against pertussis after natural infection or vaccination</article-title>. <source>Pediatr Infect Dis J</source><volume>24</volume>:<fpage>S58</fpage>–<lpage>S61</lpage>. <pub-id pub-id-type="doi">10.1097/01.inf.0000160914.59160.41</pub-id>.<pub-id pub-id-type="pmid">15876927</pub-id></mixed-citation>
              </ref>
              <ref id="B16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wilk</surname><given-names>MM</given-names></string-name>, <string-name><surname>Misiak</surname><given-names>A</given-names></string-name>, <string-name><surname>McManus</surname><given-names>RM</given-names></string-name>, <string-name><surname>Allen</surname><given-names>AC</given-names></string-name>, <string-name><surname>Lynch</surname><given-names>MA</given-names></string-name>, <string-name><surname>Mills</surname><given-names>KHG</given-names></string-name></person-group>. <year>2017</year>. <article-title>Lung CD4 tissue-resident memory T cells mediate adaptive immunity induced by previous infection of mice with <italic toggle="yes">Bordetella pertussis</italic></article-title>. <source>J Immunol</source><volume>199</volume>:<fpage>233</fpage>–<lpage>243</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1602051</pub-id>.<pub-id pub-id-type="pmid">28533445</pub-id></mixed-citation>
              </ref>
              <ref id="B17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>K</given-names></string-name>, <string-name><surname>Magri</surname><given-names>G</given-names></string-name>, <string-name><surname>Grasset</surname><given-names>EK</given-names></string-name>, <string-name><surname>Cerutti</surname><given-names>A</given-names></string-name></person-group>. <year>2020</year>. <article-title>Rethinking mucosal antibody responses: IgM, IgG, and IgD join IgA</article-title>. <source>Nat Rev Immunol</source><volume>20</volume>:<fpage>427</fpage>–<lpage>441</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-019-0261-1</pub-id>.<pub-id pub-id-type="pmid">32015473</pub-id></mixed-citation>
              </ref>
              <ref id="B18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goodman</surname><given-names>YE</given-names></string-name>, <string-name><surname>Wort</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>FL</given-names></string-name></person-group>. <year>1981</year>. <article-title>Enzyme-linked immunosorbent assay for detection of pertussis immunoglobulin A in nasopharyngeal secretions as an indicator of recent infection</article-title>. <source>J Clin Microbiol</source><volume>13</volume>:<fpage>286</fpage>–<lpage>292</lpage>. <pub-id pub-id-type="doi">10.1128/jcm.13.2.286-292.1981</pub-id>.<pub-id pub-id-type="pmid">6259201</pub-id></mixed-citation>
              </ref>
              <ref id="B19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tuomanen</surname><given-names>EI</given-names></string-name>, <string-name><surname>Zapiain</surname><given-names>LA</given-names></string-name>, <string-name><surname>Galvan</surname><given-names>P</given-names></string-name>, <string-name><surname>Hewlett</surname><given-names>EL</given-names></string-name></person-group>. <year>1984</year>. <article-title>Characterization of antibody inhibiting adherence of <italic toggle="yes">Bordetella pertussis</italic> to human respiratory epithelial cells</article-title>. <source>J Clin Microbiol</source><volume>20</volume>:<fpage>167</fpage>–<lpage>170</lpage>. <pub-id pub-id-type="doi">10.1128/jcm.20.2.167-170.1984</pub-id>.<pub-id pub-id-type="pmid">6092416</pub-id></mixed-citation>
              </ref>
              <ref id="B20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hellwig</surname><given-names>SMM</given-names></string-name>, <string-name><surname>Van Spriel</surname><given-names>AB</given-names></string-name>, <string-name><surname>Schellekens</surname><given-names>JFP</given-names></string-name>, <string-name><surname>Mooi</surname><given-names>FR</given-names></string-name>, <string-name><surname>Van de Winkel</surname><given-names>JGJ</given-names></string-name></person-group>. <year>2001</year>. <article-title>Immunoglobulin A-mediated protection against <italic toggle="yes">Bordetella pertussis</italic> infection</article-title>. <source>Infect Immun</source><volume>69</volume>:<fpage>4846</fpage>–<lpage>4850</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.69.8.4846-4850.2001</pub-id>.<pub-id pub-id-type="pmid">11447159</pub-id></mixed-citation>
              </ref>
              <ref id="B21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thomas</surname><given-names>MG</given-names></string-name>, <string-name><surname>Redhead</surname><given-names>K</given-names></string-name>, <string-name><surname>Lambert</surname><given-names>HP</given-names></string-name></person-group>. <year>1989</year>. <article-title>Human serum antibody responses to <italic toggle="yes">Bordetella pertussis</italic> infection and pertussis vaccination</article-title>. <source>J Infect Dis</source><volume>159</volume>:<fpage>211</fpage>–<lpage>218</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/159.2.211</pub-id>.<pub-id pub-id-type="pmid">2536779</pub-id></mixed-citation>
              </ref>
              <ref id="B22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marcellini</surname><given-names>V</given-names></string-name>, <string-name><surname>Piano</surname><given-names>ME</given-names></string-name>, <string-name><surname>Fedele</surname><given-names>G</given-names></string-name>, <string-name><surname>Gesualdo</surname><given-names>F</given-names></string-name>, <string-name><surname>Pandolfi</surname><given-names>E</given-names></string-name>, <string-name><surname>Midulla</surname><given-names>F</given-names></string-name>, <string-name><surname>Leone</surname><given-names>P</given-names></string-name>, <string-name><surname>Stefanelli</surname><given-names>P</given-names></string-name>, <string-name><surname>Tozzi</surname><given-names>AE</given-names></string-name>, <string-name><surname>Carsetti</surname><given-names>R</given-names></string-name></person-group>. <year>2017</year>. <article-title>Protection against pertussis in humans correlates to elevated serum antibodies and memory B cells</article-title><source>Front Immunol</source><volume>8</volume>:<fpage>1158</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2017.01158</pub-id>.<pub-id pub-id-type="pmid">28966622</pub-id></mixed-citation>
              </ref>
              <ref id="B23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mills</surname><given-names>KH</given-names></string-name>, <string-name><surname>Barnard</surname><given-names>A</given-names></string-name>, <string-name><surname>Watkins</surname><given-names>J</given-names></string-name>, <string-name><surname>Redhead</surname><given-names>K</given-names></string-name></person-group>. <year>1993</year>. <article-title>Cell-mediated immunity to <italic toggle="yes">Bordetella pertussis</italic>: role of Th1 cells in bacterial clearance in a murine respiratory infection model</article-title>. <source>Infect Immun</source><volume>61</volume>:<fpage>399</fpage>–<lpage>410</lpage>. <pub-id pub-id-type="doi">10.1128/iai.61.2.399-410.1993</pub-id>.<pub-id pub-id-type="pmid">8423070</pub-id></mixed-citation>
              </ref>
              <ref id="B24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dunne</surname><given-names>A</given-names></string-name>, <string-name><surname>Ross</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Pospisilova</surname><given-names>E</given-names></string-name>, <string-name><surname>Masin</surname><given-names>J</given-names></string-name>, <string-name><surname>Meaney</surname><given-names>A</given-names></string-name>, <string-name><surname>Sutton</surname><given-names>CE</given-names></string-name>, <string-name><surname>Iwakura</surname><given-names>Y</given-names></string-name>, <string-name><surname>Tschopp</surname><given-names>J</given-names></string-name>, <string-name><surname>Sebo</surname><given-names>P</given-names></string-name>, <string-name><surname>Mills</surname><given-names>KHG</given-names></string-name></person-group>. <year>2010</year>. <article-title>Inflammasome activation by adenylate cyclase toxin directs Th17 responses and protection against <italic toggle="yes">Bordetella pertussis</italic></article-title>. <source>J Immunol</source><volume>185</volume>:<fpage>1711</fpage>–<lpage>1719</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1000105</pub-id>.<pub-id pub-id-type="pmid">20610650</pub-id></mixed-citation>
              </ref>
              <ref id="B25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Warfel</surname><given-names>JM</given-names></string-name>, <string-name><surname>Merkel</surname><given-names>TJ</given-names></string-name></person-group>. <year>2013</year>. <article-title><italic toggle="yes">Bordetella pertussis</italic> infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates</article-title>. <source>Mucosal Immunol</source><volume>6</volume>:<fpage>787</fpage>–<lpage>796</lpage>. <pub-id pub-id-type="doi">10.1038/mi.2012.117</pub-id>.<pub-id pub-id-type="pmid">23187316</pub-id></mixed-citation>
              </ref>
              <ref id="B26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Solans</surname><given-names>L</given-names></string-name>, <string-name><surname>Locht</surname><given-names>C</given-names></string-name></person-group>. <year>2019</year>. <article-title>The role of mucosal immunity in pertussis</article-title>. <source>Front Immunol</source><volume>9</volume>:<fpage>3068</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.03068</pub-id>.<pub-id pub-id-type="pmid">30692990</pub-id></mixed-citation>
              </ref>
              <ref id="B27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boehm</surname><given-names>DT</given-names></string-name>, <string-name><surname>Wolf</surname><given-names>MA</given-names></string-name>, <string-name><surname>Hall</surname><given-names>JM</given-names></string-name>, <string-name><surname>Wong</surname><given-names>TY</given-names></string-name>, <string-name><surname>Sen-Kilic</surname><given-names>E</given-names></string-name>, <string-name><surname>Basinger</surname><given-names>HD</given-names></string-name>, <string-name><surname>Dziadowicz</surname><given-names>SA</given-names></string-name>, <string-name><surname>Gutierrez</surname><given-names>M</given-names></string-name>, <string-name><surname>de la</surname><given-names>P</given-names></string-name>, <string-name><surname>Blackwood</surname><given-names>CB</given-names></string-name>, <string-name><surname>Bradford</surname><given-names>SD</given-names></string-name>, <string-name><surname>Begley</surname><given-names>KA</given-names></string-name>, <string-name><surname>Witt</surname><given-names>WT</given-names></string-name>, <string-name><surname>Varney</surname><given-names>ME</given-names></string-name>, <string-name><surname>Barbier</surname><given-names>M</given-names></string-name>, <string-name><surname>Damron</surname><given-names>FH</given-names></string-name></person-group>. <year>2019</year>. <article-title>Intranasal acellular pertussis vaccine provides mucosal immunity and protects mice from <italic toggle="yes">Bordetella pertussis</italic></article-title>. <source>NPJ Vaccines</source><volume>4</volume>:<fpage>40</fpage>. <pub-id pub-id-type="doi">10.1038/s41541-019-0136-2</pub-id>.<pub-id pub-id-type="pmid">31602318</pub-id></mixed-citation>
              </ref>
              <ref id="B28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wolf</surname><given-names>MA</given-names></string-name>, <string-name><surname>Boehm</surname><given-names>DT</given-names></string-name>, <string-name><surname>DeJong</surname><given-names>MA</given-names></string-name>, <string-name><surname>Wong</surname><given-names>TY</given-names></string-name>, <string-name><surname>Sen-Kilic</surname><given-names>E</given-names></string-name>, <string-name><surname>Hall</surname><given-names>JM</given-names></string-name>, <string-name><surname>Blackwood</surname><given-names>CB</given-names></string-name>, <string-name><surname>Weaver</surname><given-names>KL</given-names></string-name>, <string-name><surname>Kelly</surname><given-names>CO</given-names></string-name>, <string-name><surname>Kisamore</surname><given-names>CA</given-names></string-name>, <string-name><surname>Bitzer</surname><given-names>GJ</given-names></string-name>, <string-name><surname>Bevere</surname><given-names>JR</given-names></string-name>, <string-name><surname>Barbier</surname><given-names>M</given-names></string-name>, <string-name><surname>Damron</surname><given-names>FH</given-names></string-name></person-group>. <year>2020</year>. <article-title>Intranasal immunization with acellular pertussis vaccines results in long-term immunity to <italic toggle="yes">Bordetella pertussis</italic> in mice</article-title>. <source>Infect Immun</source><volume>89</volume>:<elocation-id>e00607-20</elocation-id>. <pub-id pub-id-type="doi">10.1128/IAI.00607-20</pub-id>.</mixed-citation>
              </ref>
              <ref id="B29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maurer</surname><given-names>H</given-names></string-name>, <string-name><surname>Höfler</surname><given-names>K</given-names></string-name>, <string-name><surname>Hilbe</surname><given-names>W</given-names></string-name>, <string-name><surname>Huber</surname><given-names>E</given-names></string-name></person-group>. <year>1979</year>. <article-title>Preliminary findings with oral whooping cough vaccination in young infants</article-title>. <source>Wien Klin Wochenschr</source><volume>91</volume>:<fpage>717</fpage>–<lpage>720</lpage>. (In German.)<pub-id pub-id-type="pmid">516740</pub-id></mixed-citation>
              </ref>
              <ref id="B30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baumann</surname><given-names>E</given-names></string-name>, <string-name><surname>Binder</surname><given-names>BR</given-names></string-name>, <string-name><surname>Falk</surname><given-names>W</given-names></string-name>, <string-name><surname>Huber</surname><given-names>EG</given-names></string-name>, <string-name><surname>Kurz</surname><given-names>R</given-names></string-name>, <string-name><surname>Rosanelli</surname><given-names>K</given-names></string-name></person-group>. <year>1985</year>. <article-title>Development and clinical use of an oral heat-inactivated whole cell pertussis vaccine</article-title>. <source>Dev Biol Stand</source><volume>61</volume>:<fpage>511</fpage>–<lpage>516</lpage>.<pub-id pub-id-type="pmid">2872129</pub-id></mixed-citation>
              </ref>
              <ref id="B31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guzman</surname><given-names>CA</given-names></string-name>, <string-name><surname>Brownlie</surname><given-names>RM</given-names></string-name>, <string-name><surname>Kadurugamuwa</surname><given-names>J</given-names></string-name>, <string-name><surname>Walker</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Timmis</surname><given-names>KN</given-names></string-name></person-group>. <year>1991</year>. <article-title>Antibody responses in the lungs of mice following oral immunization with <italic toggle="yes">Salmonella</italic> Typhimurium aroA and invasive <italic toggle="yes">Escherichia coli</italic> strains expressing the filamentous hemagglutinin of <italic toggle="yes">Bordetella pertussis</italic></article-title>. <source>Infect Immun</source><volume>59</volume>:<fpage>4391</fpage>–<lpage>4397</lpage>. <pub-id pub-id-type="doi">10.1128/iai.59.12.4391-4397.1991</pub-id>.<pub-id pub-id-type="pmid">1937797</pub-id></mixed-citation>
              </ref>
              <ref id="B32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lim</surname><given-names>A</given-names></string-name>, <string-name><surname>Ng</surname><given-names>JKW</given-names></string-name>, <string-name><surname>Locht</surname><given-names>C</given-names></string-name>, <string-name><surname>Alonso</surname><given-names>S</given-names></string-name></person-group>. <year>2014</year>. <article-title>Protective role of adenylate cyclase in the context of a live pertussis vaccine candidate</article-title>. <source>Microbes Infect</source><volume>16</volume>:<fpage>51</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.micinf.2013.10.002</pub-id>.<pub-id pub-id-type="pmid">24140230</pub-id></mixed-citation>
              </ref>
              <ref id="B33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Skerry</surname><given-names>CM</given-names></string-name>, <string-name><surname>Mahon</surname><given-names>BP</given-names></string-name></person-group>. <year>2011</year>. <article-title>A live, attenuated <italic toggle="yes">Bordetella pertussis</italic> vaccine provides long-term protection against virulent challenge in a murine model</article-title>. <source>Clin Vaccine Immunol</source><volume>18</volume>:<fpage>187</fpage>–<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00371-10</pub-id>.<pub-id pub-id-type="pmid">21147936</pub-id></mixed-citation>
              </ref>
              <ref id="B34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thorstensson</surname><given-names>R</given-names></string-name>, <string-name><surname>Trollfors</surname><given-names>B</given-names></string-name>, <string-name><surname>Al-Tawil</surname><given-names>N</given-names></string-name>, <string-name><surname>Jahnmatz</surname><given-names>M</given-names></string-name>, <string-name><surname>Bergström</surname><given-names>J</given-names></string-name>, <string-name><surname>Ljungman</surname><given-names>M</given-names></string-name>, <string-name><surname>Törner</surname><given-names>A</given-names></string-name>, <string-name><surname>Wehlin</surname><given-names>L</given-names></string-name>, <string-name><surname>Van Broekhoven</surname><given-names>A</given-names></string-name>, <string-name><surname>Bosman</surname><given-names>F</given-names></string-name>, <string-name><surname>Debrie</surname><given-names>AS</given-names></string-name>, <string-name><surname>Mielcarek</surname><given-names>N</given-names></string-name>, <string-name><surname>Locht</surname><given-names>C</given-names></string-name></person-group>. <year>2014</year>. <article-title>A phase I clinical study of a live attenuated <italic toggle="yes">Bordetella pertussis</italic> vaccine—BPZE1: a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers</article-title>. <source>PLoS One</source><volume>9</volume>:<elocation-id>e83449</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0083449</pub-id>.<pub-id pub-id-type="pmid">24421886</pub-id></mixed-citation>
              </ref>
              <ref id="B35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lin</surname><given-names>A</given-names></string-name>, <string-name><surname>Apostolovic</surname><given-names>D</given-names></string-name>, <string-name><surname>Jahnmatz</surname><given-names>M</given-names></string-name>, <string-name><surname>Liang</surname><given-names>F</given-names></string-name>, <string-name><surname>Ols</surname><given-names>S</given-names></string-name>, <string-name><surname>Tecleab</surname><given-names>T</given-names></string-name>, <string-name><surname>Wu</surname><given-names>C</given-names></string-name>, <string-name><surname>van Hage</surname><given-names>M</given-names></string-name>, <string-name><surname>Solovay</surname><given-names>K</given-names></string-name>, <string-name><surname>Rubin</surname><given-names>K</given-names></string-name>, <string-name><surname>Locht</surname><given-names>C</given-names></string-name>, <string-name><surname>Thorstensson</surname><given-names>R</given-names></string-name>, <string-name><surname>Thalen</surname><given-names>M</given-names></string-name>, <string-name><surname>Loré</surname><given-names>K</given-names></string-name></person-group>. <year>2020</year>. <article-title>Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans</article-title>. <source>J Clin Invest</source><volume>130</volume>:<fpage>2332</fpage>–<lpage>2346</lpage>. <pub-id pub-id-type="doi">10.1172/JCI135020</pub-id>.<pub-id pub-id-type="pmid">31945015</pub-id></mixed-citation>
              </ref>
              <ref id="B36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hornibrook</surname><given-names>JW</given-names></string-name>, <string-name><surname>Ashburn</surname><given-names>LL</given-names></string-name></person-group>. <year>1939</year>. <article-title>A study of experimental pertussis in the young rat</article-title>. <source>Public Heal Rep</source><volume>54</volume>:<fpage>439</fpage>. <pub-id pub-id-type="doi">10.2307/4582826</pub-id>.</mixed-citation>
              </ref>
              <ref id="B37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Woods</surname><given-names>DE</given-names></string-name>, <string-name><surname>Franklin</surname><given-names>R</given-names></string-name>, <string-name><surname>Cryz</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Ganss</surname><given-names>M</given-names></string-name>, <string-name><surname>Peppler</surname><given-names>M</given-names></string-name>, <string-name><surname>Ewanowich</surname><given-names>C</given-names></string-name></person-group>. <year>1989</year>. <article-title>Development of a rat model for respiratory infection with <italic toggle="yes">Bordetella pertussis</italic></article-title>. <source>Infect Immun</source><volume>57</volume>:<fpage>1018</fpage>–<lpage>1024</lpage>. <pub-id pub-id-type="doi">10.1128/iai.57.4.1018-1024.1989</pub-id>.<pub-id pub-id-type="pmid">2538394</pub-id></mixed-citation>
              </ref>
              <ref id="B38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hall</surname><given-names>E</given-names></string-name>, <string-name><surname>Parton</surname><given-names>R</given-names></string-name>, <string-name><surname>Wardlaw</surname><given-names>AC</given-names></string-name></person-group>. <year>1994</year>. <article-title>Cough production, leukocytosis, and serology of rats infected intrabronchially with <italic toggle="yes">Bordetella pertussis</italic></article-title>. <source>J Med Microbiol</source><volume>40</volume>:<fpage>205</fpage>–<lpage>213</lpage>. <pub-id pub-id-type="doi">10.1099/00222615-40-3-205</pub-id>.<pub-id pub-id-type="pmid">8114072</pub-id></mixed-citation>
              </ref>
              <ref id="B39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Parton</surname><given-names>R</given-names></string-name>, <string-name><surname>Hall</surname><given-names>E</given-names></string-name>, <string-name><surname>Wardlaw</surname><given-names>AC</given-names></string-name></person-group>. <year>1994</year>. <article-title>Responses to <italic toggle="yes">Bordetella pertussis</italic> mutant strains and to vaccination in the coughing rat model of pertussis</article-title>. <source>J Med Microbiol</source><volume>40</volume>:<fpage>307</fpage>–<lpage>312</lpage>. <pub-id pub-id-type="doi">10.1099/00222615-40-5-307</pub-id>.<pub-id pub-id-type="pmid">8176718</pub-id></mixed-citation>
              </ref>
              <ref id="B40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hall</surname><given-names>E</given-names></string-name>, <string-name><surname>Parton</surname><given-names>R</given-names></string-name>, <string-name><surname>Wardlaw</surname><given-names>AC</given-names></string-name></person-group>. <year>1997</year>. <article-title>Differences in coughing and other responses to intrabronchial infection with <italic toggle="yes">Bordetella pertussis</italic> among strains of rats</article-title>. <source>Infect Immun</source><volume>65</volume>:<fpage>4711</fpage>–<lpage>4717</lpage>. <pub-id pub-id-type="doi">10.1128/iai.65.11.4711-4717.1997</pub-id>.<pub-id pub-id-type="pmid">9353055</pub-id></mixed-citation>
              </ref>
              <ref id="B41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hall</surname><given-names>E</given-names></string-name>, <string-name><surname>Parton</surname><given-names>R</given-names></string-name>, <string-name><surname>Wardlaw</surname><given-names>AC</given-names></string-name></person-group>. <year>1998</year>. <article-title>Responses to acellular pertussis vaccines and component antigens in a coughing-rat model of pertussis</article-title>. <source>Vaccine</source><volume>16</volume>:<fpage>1595</fpage>–<lpage>1603</lpage>. <pub-id pub-id-type="doi">10.1016/S0264-410X(98)80001-7</pub-id>.<pub-id pub-id-type="pmid">9713934</pub-id></mixed-citation>
              </ref>
              <ref id="B42">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hall</surname><given-names>E</given-names></string-name>, <string-name><surname>Parton</surname><given-names>R</given-names></string-name>, <string-name><surname>Wardlaw</surname><given-names>AC</given-names></string-name></person-group>. <year>1999</year>. <article-title>Time-course of infection and responses in a coughing rat model of pertussis</article-title>. <source>J Med Microbiol</source><volume>48</volume>:<fpage>95</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1099/00222615-48-1-95</pub-id>.<pub-id pub-id-type="pmid">9920131</pub-id></mixed-citation>
              </ref>
              <ref id="B43">
                <label>43</label>
                <mixed-citation publication-type="working-paper"><person-group person-group-type="author"><string-name><surname>Hall</surname><given-names>JM</given-names></string-name>, <string-name><surname>Kang</surname><given-names>J</given-names></string-name>, <string-name><surname>Kenney</surname><given-names>SM</given-names></string-name>, <string-name><surname>Wong</surname><given-names>TY</given-names></string-name>, <string-name><surname>Bitzer</surname><given-names>GJ</given-names></string-name>, <string-name><surname>Kelly</surname><given-names>CO</given-names></string-name>, <string-name><surname>Kisamore</surname><given-names>CA</given-names></string-name>, <string-name><surname>Boehm</surname><given-names>DT</given-names></string-name>, <string-name><surname>DeJong</surname><given-names>MA</given-names></string-name>, <string-name><surname>Allison</surname><given-names>M</given-names></string-name>, <string-name><surname>Sen-Kilic</surname><given-names>E</given-names></string-name>, <string-name><surname>Horspool</surname><given-names>AM</given-names></string-name>, <string-name><surname>Bevere</surname><given-names>JR</given-names></string-name>, <string-name><surname>Barbier</surname><given-names>M</given-names></string-name>, <string-name><surname>Heath</surname><given-names>DF</given-names></string-name></person-group>. <year>2021</year>. <article-title>Re-investigating the coughing rat model of pertussis to understand <italic toggle="yes">Bordetella pertussis</italic> pathogenesis</article-title>. <source>bioRxiv</source><ext-link xlink:href="https://www.biorxiv.org/content/10.1101/2021.04.02.438291v1" ext-link-type="uri">https://www.biorxiv.org/content/10.1101/2021.04.02.438291v1</ext-link>.</mixed-citation>
              </ref>
              <ref id="B44">
                <label>44</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ross</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Sutton</surname><given-names>CE</given-names></string-name>, <string-name><surname>Higgins</surname><given-names>S</given-names></string-name>, <string-name><surname>Allen</surname><given-names>AC</given-names></string-name>, <string-name><surname>Walsh</surname><given-names>K</given-names></string-name>, <string-name><surname>Misiak</surname><given-names>A</given-names></string-name>, <string-name><surname>Lavelle</surname><given-names>EC</given-names></string-name>, <string-name><surname>McLoughlin</surname><given-names>RM</given-names></string-name>, <string-name><surname>Mills</surname><given-names>KHG</given-names></string-name></person-group>. <year>2013</year>. <article-title>Relative contribution of Th1 and Th17 cells in adaptive immunity to <italic toggle="yes">Bordetella pertussis</italic>: towards the rational design of an improved acellular pertussis vaccine</article-title>. <source>PLoS Pathog</source><volume>9</volume>:<elocation-id>e1003264</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1003264</pub-id>.<pub-id pub-id-type="pmid">23592988</pub-id></mixed-citation>
              </ref>
              <ref id="B45">
                <label>45</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ryan</surname><given-names>M</given-names></string-name>, <string-name><surname>Murphy</surname><given-names>G</given-names></string-name>, <string-name><surname>Ryan</surname><given-names>E</given-names></string-name>, <string-name><surname>Nilsson</surname><given-names>L</given-names></string-name>, <string-name><surname>Shackley</surname><given-names>F</given-names></string-name>, <string-name><surname>Gothefors</surname><given-names>L</given-names></string-name>, <string-name><surname>Øymar</surname><given-names>K</given-names></string-name>, <string-name><surname>Miller</surname><given-names>E</given-names></string-name>, <string-name><surname>Storsaeter</surname><given-names>J</given-names></string-name>, <string-name><surname>Mills</surname><given-names>KH</given-names></string-name></person-group>. <year>1998</year>. <article-title>Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children</article-title>. <source>Immunology</source><volume>93</volume>:<fpage>1</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2567.1998.00401.x</pub-id>.<pub-id pub-id-type="pmid">9536112</pub-id></mixed-citation>
              </ref>
              <ref id="B46">
                <label>46</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ausiello</surname><given-names>CM</given-names></string-name>, <string-name><surname>Urbani</surname><given-names>F</given-names></string-name>, <string-name><surname>la Sala</surname><given-names>A</given-names></string-name>, <string-name><surname>Lande</surname><given-names>R</given-names></string-name>, <string-name><surname>Cassone</surname><given-names>A</given-names></string-name></person-group>. <year>1997</year>. <article-title>Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines</article-title>. <source>Infect Immun</source><volume>65</volume>:<fpage>2168</fpage>–<lpage>2174</lpage>. <pub-id pub-id-type="doi">10.1128/iai.65.6.2168-2174.1997</pub-id>.<pub-id pub-id-type="pmid">9169747</pub-id></mixed-citation>
              </ref>
              <ref id="B47">
                <label>47</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mahon</surname><given-names>BP</given-names></string-name>, <string-name><surname>Sheahan</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Griffin</surname><given-names>F</given-names></string-name>, <string-name><surname>Murphy</surname><given-names>G</given-names></string-name>, <string-name><surname>Mills</surname><given-names>KH</given-names></string-name></person-group>. <year>1997</year>. <article-title>Atypical disease after <italic toggle="yes">Bordetella pertussis</italic> respiratory infection of mice with targeted disruptions of interferon-gamma receptor or immunoglobulin mu chain genes</article-title>. <source>J Exp Med</source><volume>186</volume>:<fpage>1843</fpage>–<lpage>1851</lpage>. <pub-id pub-id-type="doi">10.1084/jem.186.11.1843</pub-id>.<pub-id pub-id-type="pmid">9382883</pub-id></mixed-citation>
              </ref>
              <ref id="B48">
                <label>48</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barbic</surname><given-names>J</given-names></string-name>, <string-name><surname>Leef</surname><given-names>MF</given-names></string-name>, <string-name><surname>Burns</surname><given-names>DL</given-names></string-name>, <string-name><surname>Shahin</surname><given-names>RD</given-names></string-name></person-group>. <year>1997</year>. <article-title>Role of gamma interferon in natural clearance of <italic toggle="yes">Bordetella pertussis</italic> infection</article-title>. <source>Infect Immun</source><volume>65</volume>:<fpage>4904</fpage>–<lpage>4908</lpage>. <pub-id pub-id-type="doi">10.1128/iai.65.12.4904-4908.1997</pub-id>.<pub-id pub-id-type="pmid">9393774</pub-id></mixed-citation>
              </ref>
              <ref id="B49">
                <label>49</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mills</surname><given-names>KHG</given-names></string-name>, <string-name><surname>Ryan</surname><given-names>M</given-names></string-name>, <string-name><surname>Ryan</surname><given-names>E</given-names></string-name>, <string-name><surname>Mahon</surname><given-names>BP</given-names></string-name></person-group>. <year>1998</year>. <article-title>A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell- mediated immunity in protection against <italic toggle="yes">Bordetella pertussis</italic></article-title>. <source>Infect Immun</source><volume>66</volume>:<fpage>594</fpage>–<lpage>602</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.66.2.594-602.1998</pub-id>.<pub-id pub-id-type="pmid">9453614</pub-id></mixed-citation>
              </ref>
              <ref id="B50">
                <label>50</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Redhead</surname><given-names>K</given-names></string-name>, <string-name><surname>Watkins</surname><given-names>J</given-names></string-name>, <string-name><surname>Barnard</surname><given-names>A</given-names></string-name>, <string-name><surname>Mills</surname><given-names>KHG</given-names></string-name></person-group>. <year>1993</year>. <article-title>Effective immunization against <italic toggle="yes">Bordetella pertussis</italic> respiratory infection in mice is dependent on induction of cell-mediated immunity</article-title>. <source>Infect Immun</source><volume>61</volume>:<fpage>3190</fpage>–<lpage>3198</lpage>. <pub-id pub-id-type="doi">10.1128/iai.61.8.3190-3198.1993</pub-id>.<pub-id pub-id-type="pmid">8335349</pub-id></mixed-citation>
              </ref>
              <ref id="B51">
                <label>51</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sawal</surname><given-names>M</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>M</given-names></string-name>, <string-name><surname>Irazuzta</surname><given-names>JE</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>R</given-names></string-name>, <string-name><surname>Kirton</surname><given-names>C</given-names></string-name>, <string-name><surname>Brundler</surname><given-names>M-A</given-names></string-name>, <string-name><surname>Evans</surname><given-names>CA</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>JA</given-names></string-name>, <string-name><surname>Raffeeq</surname><given-names>P</given-names></string-name>, <string-name><surname>Azaz</surname><given-names>A</given-names></string-name>, <string-name><surname>Rotta</surname><given-names>AT</given-names></string-name>, <string-name><surname>Vora</surname><given-names>A</given-names></string-name>, <string-name><surname>Vohra</surname><given-names>A</given-names></string-name>, <string-name><surname>Abboud</surname><given-names>P</given-names></string-name>, <string-name><surname>Mirkin</surname><given-names>LD</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>M</given-names></string-name>, <string-name><surname>Dishop</surname><given-names>MK</given-names></string-name>, <string-name><surname>Graf</surname><given-names>JM</given-names></string-name>, <string-name><surname>Petros</surname><given-names>A</given-names></string-name>, <string-name><surname>Klonin</surname><given-names>H</given-names></string-name></person-group>. <year>2009</year>. <article-title>Fulminant pertussis: a multi-center study with new insights into the clinico-pathological mechanisms</article-title>. <source>Pediatr Pulmonol</source><volume>44</volume>:<fpage>970</fpage>–<lpage>980</lpage>. <pub-id pub-id-type="doi">10.1002/ppul.21082</pub-id>.<pub-id pub-id-type="pmid">19725100</pub-id></mixed-citation>
              </ref>
              <ref id="B52">
                <label>52</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Paddock</surname><given-names>CD</given-names></string-name>, <string-name><surname>Sanden</surname><given-names>GN</given-names></string-name>, <string-name><surname>Cherry</surname><given-names>JD</given-names></string-name>, <string-name><surname>Gal</surname><given-names>AA</given-names></string-name>, <string-name><surname>Langston</surname><given-names>C</given-names></string-name>, <string-name><surname>Tatti</surname><given-names>KM</given-names></string-name>, <string-name><surname>Wu</surname><given-names>K</given-names></string-name>, <string-name><surname>Goldsmith</surname><given-names>CS</given-names></string-name>, <string-name><surname>Greer</surname><given-names>PW</given-names></string-name>, <string-name><surname>Montague</surname><given-names>JL</given-names></string-name>, <string-name><surname>Eliason</surname><given-names>MT</given-names></string-name>, <string-name><surname>Holman</surname><given-names>RC</given-names></string-name>, <string-name><surname>Guarner</surname><given-names>J</given-names></string-name>, <string-name><surname>Shieh</surname><given-names>W</given-names></string-name>, <string-name><surname>Zaki</surname><given-names>SR</given-names></string-name></person-group>. <year>2008</year>. <article-title>Pathology and pathogenesis of fatal <italic toggle="yes">Bordetella pertussis</italic> infection in infants</article-title>. <source>Clin Infect Dis</source><volume>47</volume>:<fpage>328</fpage>–<lpage>338</lpage>. <pub-id pub-id-type="doi">10.1086/589753</pub-id>.<pub-id pub-id-type="pmid">18558873</pub-id></mixed-citation>
              </ref>
              <ref id="B53">
                <label>53</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morse</surname><given-names>SI</given-names></string-name>, <string-name><surname>Morse</surname><given-names>JH</given-names></string-name></person-group>. <year>1976</year>. <article-title>Isolation and properties of the leukocytosis- and lymphocytosis- promoting factor of <italic toggle="yes">Bordetella pertussis</italic></article-title>. <source>J Exp Med</source><volume>143</volume>:<fpage>1483</fpage>–<lpage>1502</lpage>. <pub-id pub-id-type="doi">10.1084/jem.143.6.1483</pub-id>.<pub-id pub-id-type="pmid">58054</pub-id></mixed-citation>
              </ref>
              <ref id="B54">
                <label>54</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morse</surname><given-names>SI</given-names></string-name></person-group>. <year>1965</year>. <article-title>Studies on the lymphocytosis induced in mice by <italic toggle="yes">Bordetella pertussis</italic></article-title>. <source>J Exp Med</source><volume>121</volume>:<fpage>49</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1084/jem.121.1.49</pub-id>.<pub-id pub-id-type="pmid">14253487</pub-id></mixed-citation>
              </ref>
              <ref id="B55">
                <label>55</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morse</surname><given-names>SI</given-names></string-name>, <string-name><surname>Riester</surname><given-names>SK</given-names></string-name></person-group>. <year>1967</year>. <article-title>Studies on the leukocytosis and lymphocytosis induced by <italic toggle="yes">Bordetella pertussis</italic>. I. Radioautographic analysis of the circulating cells in mice undergoing pertussis-induced hyperleukocytosis</article-title>. <source>J Exp Med</source><volume>125</volume>:<fpage>401</fpage>–<lpage>408</lpage>. <pub-id pub-id-type="doi">10.1084/jem.125.3.401</pub-id>.<pub-id pub-id-type="pmid">4289293</pub-id></mixed-citation>
              </ref>
              <ref id="B56">
                <label>56</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heininger</surname><given-names>U</given-names></string-name>, <string-name><surname>Klich</surname><given-names>K</given-names></string-name>, <string-name><surname>Stehr</surname><given-names>K</given-names></string-name>, <string-name><surname>Cherry</surname><given-names>JD</given-names></string-name></person-group>. <year>1997</year>. <article-title>Clinical findings in <italic toggle="yes">Bordetella pertussis</italic> infections: results of a prospective multicenter surveillance study</article-title>. <source>Pediatrics</source><volume>100</volume>:<fpage>E10</fpage>–<lpage>E10</lpage>. <pub-id pub-id-type="doi">10.1542/peds.100.6.e10</pub-id>.</mixed-citation>
              </ref>
              <ref id="B57">
                <label>57</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Blackwood</surname><given-names>CB</given-names></string-name>, <string-name><surname>Sen-Kilic</surname><given-names>E</given-names></string-name>, <string-name><surname>Boehm</surname><given-names>DT</given-names></string-name>, <string-name><surname>Hall</surname><given-names>JM</given-names></string-name>, <string-name><surname>Varney</surname><given-names>ME</given-names></string-name>, <string-name><surname>Wong</surname><given-names>TY</given-names></string-name>, <string-name><surname>Bradford</surname><given-names>SD</given-names></string-name>, <string-name><surname>Bevere</surname><given-names>JR</given-names></string-name>, <string-name><surname>Witt</surname><given-names>WT</given-names></string-name>, <string-name><surname>Damron</surname><given-names>FH</given-names></string-name>, <string-name><surname>Barbier</surname><given-names>M</given-names></string-name></person-group>. <year>2020</year>. <article-title>Innate and adaptive immune responses against <italic toggle="yes">Bordetella pertussis</italic> and <italic toggle="yes">Pseudomonas aeruginosa</italic> in a murine model of mucosal vaccination against respiratory infection</article-title>. <source>Vaccines</source><volume>8</volume>:<fpage>1</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.3390/vaccines8040647</pub-id>.</mixed-citation>
              </ref>
              <ref id="B58">
                <label>58</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bewick</surname><given-names>V</given-names></string-name>, <string-name><surname>Cheek</surname><given-names>L</given-names></string-name>, <string-name><surname>Ball</surname><given-names>J</given-names></string-name></person-group>. <year>2003</year>. <article-title>Statistics review 7: correlation and regression</article-title>. <source>Crit Care</source><volume>7</volume>:<fpage>451</fpage>–<lpage>459</lpage>. <pub-id pub-id-type="doi">10.1186/cc2401</pub-id>.<pub-id pub-id-type="pmid">14624685</pub-id></mixed-citation>
              </ref>
              <ref id="B59">
                <label>59</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Klein</surname><given-names>NP</given-names></string-name>, <string-name><surname>Bartlett</surname><given-names>J</given-names></string-name>, <string-name><surname>Fireman</surname><given-names>B</given-names></string-name>, <string-name><surname>Aukes</surname><given-names>L</given-names></string-name>, <string-name><surname>Buck</surname><given-names>PO</given-names></string-name>, <string-name><surname>Krishnarajah</surname><given-names>G</given-names></string-name>, <string-name><surname>Baxter</surname><given-names>R</given-names></string-name></person-group>. <year>2017</year>. <article-title>Waning protection following five doses of a three-component diphtheria, tetanus, and acellular pertussis vaccine</article-title>. <source>Vaccine</source><volume>35</volume>:<fpage>3395</fpage>–<lpage>3400</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.05.008</pub-id>.<pub-id pub-id-type="pmid">28506516</pub-id></mixed-citation>
              </ref>
              <ref id="B60">
                <label>60</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nakamura</surname><given-names>K</given-names></string-name>, <string-name><surname>Shinoda</surname><given-names>N</given-names></string-name>, <string-name><surname>Hiramatsu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ohnishi</surname><given-names>S</given-names></string-name>, <string-name><surname>Kamitani</surname><given-names>S</given-names></string-name>, <string-name><surname>Ogura</surname><given-names>Y</given-names></string-name>, <string-name><surname>Hayashi</surname><given-names>T</given-names></string-name>, <string-name><surname>Horiguchi</surname><given-names>Y</given-names></string-name></person-group>. <year>2019</year>. <article-title>BspR/BtrA, an anti-σ factor, regulates the ability of <italic toggle="yes">Bordetella bronchiseptica</italic> to cause cough in rats</article-title>. <source>mSphere</source><pub-id pub-id-type="doi">10.1128/mSphere.00093-19</pub-id>.</mixed-citation>
              </ref>
              <ref id="B61">
                <label>61</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hall</surname><given-names>JM</given-names></string-name>, <string-name><surname>Kang</surname><given-names>J</given-names></string-name>, <string-name><surname>Kenney</surname><given-names>SM</given-names></string-name>, <string-name><surname>Wong</surname><given-names>TY</given-names></string-name>, <string-name><surname>Bitzer</surname><given-names>GJ</given-names></string-name>, <string-name><surname>Kelly</surname><given-names>CO</given-names></string-name>, <string-name><surname>Kisamore</surname><given-names>CA</given-names></string-name>, <string-name><surname>Boehm</surname><given-names>DT</given-names></string-name>, <string-name><surname>DeJong</surname><given-names>MA</given-names></string-name>, <string-name><surname>Wolf</surname><given-names>MA</given-names></string-name>, <string-name><surname>Sen-Kilic</surname><given-names>E</given-names></string-name>, <string-name><surname>Horspool</surname><given-names>AM</given-names></string-name>, <string-name><surname>Bevere</surname><given-names>JR</given-names></string-name>, <string-name><surname>Barbier</surname><given-names>M</given-names></string-name>, <string-name><surname>Damron</surname><given-names>FH</given-names></string-name></person-group>. <year>2021</year>. <article-title>Re-investigating the coughing rat model of pertussis to understand <italic toggle="yes">Bordetella pertussis</italic> pathogenesis</article-title>. <source>Infect Immun</source><volume>89</volume>:<elocation-id>e00304-21</elocation-id>. <pub-id pub-id-type="doi">10.1128/IAI.00304-21</pub-id>.</mixed-citation>
              </ref>
              <ref id="B62">
                <label>62</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boehm</surname><given-names>DT</given-names></string-name>, <string-name><surname>Hall</surname><given-names>JM</given-names></string-name>, <string-name><surname>Wong</surname><given-names>TY</given-names></string-name>, <string-name><surname>DiVenere</surname><given-names>A</given-names></string-name>, <string-name><surname>Sen-Kilic</surname><given-names>E</given-names></string-name>, <string-name><surname>Bevere</surname><given-names>JR</given-names></string-name>, <string-name><surname>Bradford</surname><given-names>SD</given-names></string-name>, <string-name><surname>Blackwood</surname><given-names>CB</given-names></string-name>, <string-name><surname>Elkins</surname><given-names>C</given-names></string-name>, <string-name><surname>DeRoos</surname><given-names>KA</given-names></string-name>, <string-name><surname>Gray</surname><given-names>MC</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>CG</given-names></string-name>, <string-name><surname>Varney</surname><given-names>ME</given-names></string-name>, <string-name><surname>Maynard</surname><given-names>JA</given-names></string-name>, <string-name><surname>Hewlett</surname><given-names>EL</given-names></string-name>, <string-name><surname>Barbier</surname><given-names>M</given-names></string-name>, <string-name><surname>Damron</surname><given-names>FH</given-names></string-name></person-group>. <year>2018</year>. <article-title>Evaluation of adenylate cyclase toxoid antigen in acellular pertussis vaccines using a <italic toggle="yes">Bordetella pertussis</italic> challenge model in mice</article-title>. <source>Infect Immun</source><volume>86</volume>:<elocation-id>e00857-17</elocation-id>. <pub-id pub-id-type="doi">10.1128/IAI.00857-17</pub-id>.<pub-id pub-id-type="pmid">30012638</pub-id></mixed-citation>
              </ref>
              <ref id="B63">
                <label>63</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shi</surname><given-names>W</given-names></string-name>, <string-name><surname>Kou</surname><given-names>Y</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>H</given-names></string-name>, <string-name><surname>Gao</surname><given-names>F</given-names></string-name>, <string-name><surname>Kong</surname><given-names>W</given-names></string-name>, <string-name><surname>Su</surname><given-names>W</given-names></string-name>, <string-name><surname>Xu</surname><given-names>F</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>C</given-names></string-name></person-group>. <year>2018</year>. <article-title>Novel intranasal pertussis vaccine based on bacterium-like particles as a mucosal adjuvant</article-title>. <source>Immunol Lett</source><volume>198</volume>:<fpage>26</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.imlet.2018.03.012</pub-id>.<pub-id pub-id-type="pmid">29601940</pub-id></mixed-citation>
              </ref>
              <ref id="B64">
                <label>64</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Allen</surname><given-names>AC</given-names></string-name>, <string-name><surname>Wilk</surname><given-names>MM</given-names></string-name>, <string-name><surname>Misiak</surname><given-names>A</given-names></string-name>, <string-name><surname>Borkner</surname><given-names>L</given-names></string-name>, <string-name><surname>Murphy</surname><given-names>D</given-names></string-name>, <string-name><surname>Mills</surname><given-names>KHG</given-names></string-name></person-group>. <year>2018</year>. <article-title>Sustained protective immunity against <italic toggle="yes">Bordetella pertussis</italic> nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting T RM cells</article-title>. <source>Mucosal Immunol</source><volume>11</volume>:<fpage>1763</fpage>–<lpage>1776</lpage>. <pub-id pub-id-type="doi">10.1038/s41385-018-0080-x</pub-id>.<pub-id pub-id-type="pmid">30127384</pub-id></mixed-citation>
              </ref>
              <ref id="B65">
                <label>65</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ryan</surname><given-names>EJ</given-names></string-name>, <string-name><surname>McNeela</surname><given-names>E</given-names></string-name>, <string-name><surname>Murphy</surname><given-names>GA</given-names></string-name>, <string-name><surname>Stewart</surname><given-names>H</given-names></string-name>, <string-name><surname>O’Hagan</surname><given-names>D</given-names></string-name>, <string-name><surname>Pizza</surname><given-names>M</given-names></string-name>, <string-name><surname>Rappuoli</surname><given-names>R</given-names></string-name>, <string-name><surname>Mills</surname><given-names>KH</given-names></string-name></person-group>. <year>1999</year>. <article-title>Mutants of <italic toggle="yes">Escherichia coli</italic> heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells</article-title>. <source>Infect Immun</source><volume>67</volume>:<fpage>6270</fpage>–<lpage>6280</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.67.12.6270-6280.1999</pub-id>.<pub-id pub-id-type="pmid">10569737</pub-id></mixed-citation>
              </ref>
              <ref id="B66">
                <label>66</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Locht</surname><given-names>C</given-names></string-name>, <string-name><surname>Papin</surname><given-names>JF</given-names></string-name>, <string-name><surname>Lecher</surname><given-names>S</given-names></string-name>, <string-name><surname>Debrie</surname><given-names>A-S</given-names></string-name>, <string-name><surname>Thalen</surname><given-names>M</given-names></string-name>, <string-name><surname>Solovay</surname><given-names>K</given-names></string-name>, <string-name><surname>Rubin</surname><given-names>K</given-names></string-name>, <string-name><surname>Mielcarek</surname><given-names>N</given-names></string-name></person-group>. <year>2017</year>. <article-title>Live attenuated pertussis vaccine BPZE1 protects baboons against <italic toggle="yes">Bordetella pertussis</italic> disease and infection</article-title>. <source>J Infect Dis</source><volume>216</volume>:<fpage>117</fpage>–<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jix254</pub-id>.<pub-id pub-id-type="pmid">28535276</pub-id></mixed-citation>
              </ref>
              <ref id="B67">
                <label>67</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Solans</surname><given-names>L</given-names></string-name>, <string-name><surname>Debrie</surname><given-names>A-S</given-names></string-name>, <string-name><surname>Borkner</surname><given-names>L</given-names></string-name>, <string-name><surname>Aguiló</surname><given-names>N</given-names></string-name>, <string-name><surname>Thiriard</surname><given-names>A</given-names></string-name>, <string-name><surname>Coutte</surname><given-names>L</given-names></string-name>, <string-name><surname>Uranga</surname><given-names>S</given-names></string-name>, <string-name><surname>Trottein</surname><given-names>F</given-names></string-name>, <string-name><surname>Martín</surname><given-names>C</given-names></string-name>, <string-name><surname>Mills</surname><given-names>KHG</given-names></string-name>, <string-name><surname>Locht</surname><given-names>C</given-names></string-name></person-group>. <year>2018</year>. <article-title>IL-17-dependent SIgA-mediated protection against nasal <italic toggle="yes">Bordetella pertussis</italic> infection by live attenuated BPZE1 vaccine</article-title>. <source>Mucosal Immunol</source><volume>11</volume>:<fpage>1753</fpage>–<lpage>1762</lpage>. <pub-id pub-id-type="doi">10.1038/s41385-018-0073-9</pub-id>.<pub-id pub-id-type="pmid">30115992</pub-id></mixed-citation>
              </ref>
              <ref id="B68">
                <label>68</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Strugnell</surname><given-names>R</given-names></string-name>, <string-name><surname>Dougan</surname><given-names>G</given-names></string-name>, <string-name><surname>Chatfield</surname><given-names>S</given-names></string-name>, <string-name><surname>Charles</surname><given-names>I</given-names></string-name>, <string-name><surname>Fairweather</surname><given-names>N</given-names></string-name>, <string-name><surname>Tite</surname><given-names>J</given-names></string-name>, <string-name><surname>Li</surname><given-names>JL</given-names></string-name>, <string-name><surname>Beesley</surname><given-names>J</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>M</given-names></string-name></person-group>. <year>1992</year>. <article-title>Characterization of a <italic toggle="yes">Salmonella</italic> Typhimurium Aro vaccine strain expressing the P.69 antigen of <italic toggle="yes">Bordetella pertussis</italic></article-title>. <source>Infect Immun</source><volume>60</volume>:<fpage>3994</fpage>–<lpage>4002</lpage>. <pub-id pub-id-type="doi">10.1128/iai.60.10.3994-4002.1992</pub-id>.<pub-id pub-id-type="pmid">1398911</pub-id></mixed-citation>
              </ref>
              <ref id="B69">
                <label>69</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Molina</surname><given-names>NC</given-names></string-name>, <string-name><surname>Parker</surname><given-names>CD</given-names></string-name></person-group>. <year>1990</year>. <article-title>Murine antibody response to oral infection with live aroA recombinant <italic toggle="yes">Salmonella dublin</italic> vaccine strains expressing filamentous hemagglutinin antigen from <italic toggle="yes">Bordetella pertussis</italic></article-title>. <source>Infect Immun</source><volume>58</volume>:<fpage>2523</fpage>–<lpage>2528</lpage>. <pub-id pub-id-type="doi">10.1128/iai.58.8.2523-2528.1990</pub-id>.<pub-id pub-id-type="pmid">2370105</pub-id></mixed-citation>
              </ref>
              <ref id="B70">
                <label>70</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Plotkin</surname><given-names>SA</given-names></string-name></person-group>. <year>2010</year>. <article-title>Correlates of protection induced by vaccination</article-title>. <source>Clin Vaccine Immunol</source><volume>17</volume>:<fpage>1055</fpage>–<lpage>1065</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00131-10</pub-id>.<pub-id pub-id-type="pmid">20463105</pub-id></mixed-citation>
              </ref>
              <ref id="B71">
                <label>71</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Murphy</surname><given-names>TV</given-names></string-name>, <string-name><surname>Slade</surname><given-names>BA</given-names></string-name>, <string-name><surname>Broder</surname><given-names>KR</given-names></string-name>, <string-name><surname>Kretsinger</surname><given-names>K</given-names></string-name>, <string-name><surname>Tiwari</surname><given-names>T</given-names></string-name>, <string-name><surname>Joyce</surname><given-names>PM</given-names></string-name>, <string-name><surname>Brown</surname><given-names>K</given-names></string-name>, <string-name><surname>Iskander</surname><given-names>JK</given-names></string-name>, <string-name><surname>Brown</surname><given-names>K</given-names></string-name>, <string-name><surname>Moran</surname><given-names>JS</given-names></string-name></person-group>, <collab>ACIP Centers/CDC</collab>. <year>2008</year>. <article-title>Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants: recommendations of the Advisory Committee on Immunization Practices (ACIP)</article-title>. <source>MMWR Recomm Rep</source><volume>57</volume><issue>(RR-4)</issue>:<fpage>1</fpage>–<lpage>51</lpage>.</mixed-citation>
              </ref>
              <ref id="B72">
                <label>72</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Frizzell</surname><given-names>H</given-names></string-name>, <string-name><surname>Woodrow</surname><given-names>KA</given-names></string-name></person-group>. <year>2020</year>. <article-title>Biomaterial approaches for understanding and overcoming immunological barriers to effective oral vaccinations</article-title>. <source>Adv Funct Mater</source><volume>30</volume>:<fpage>1907170</fpage>. <pub-id pub-id-type="doi">10.1002/adfm.201907170</pub-id>.</mixed-citation>
              </ref>
              <ref id="B73">
                <label>73</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Azizi</surname><given-names>A</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>A</given-names></string-name>, <string-name><surname>Diaz-Mitoma</surname><given-names>F</given-names></string-name>, <string-name><surname>Mestecky</surname><given-names>J</given-names></string-name></person-group>. <year>2010</year>. <article-title>Enhancing oral vaccine potency by targeting intestinal M cells</article-title>. <source>PLoS Pathog</source><volume>6</volume>:<elocation-id>e1001147</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1001147</pub-id>.<pub-id pub-id-type="pmid">21085599</pub-id></mixed-citation>
              </ref>
              <ref id="B74">
                <label>74</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kilgore</surname><given-names>PE</given-names></string-name>, <string-name><surname>Salim</surname><given-names>AM</given-names></string-name>, <string-name><surname>Zervos</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Schmitt</surname><given-names>H-J</given-names></string-name></person-group>. <year>2016</year>. <article-title>Pertussis: microbiology, disease, treatment, and prevention</article-title>. <source>Clin Microbiol Rev</source><volume>29</volume>:<fpage>449</fpage>–<lpage>486</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.00083-15</pub-id>.<pub-id pub-id-type="pmid">27029594</pub-id></mixed-citation>
              </ref>
              <ref id="B75">
                <label>75</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scheller</surname><given-names>EV</given-names></string-name>, <string-name><surname>Cotter</surname><given-names>PA</given-names></string-name></person-group>. <year>2015</year>. <article-title><italic toggle="yes">Bordetella</italic> filamentous hemagglutinin and fimbriae: critical adhesins with unrealized vaccine potential</article-title>. <source>Pathog Dis</source><volume>73</volume>:<fpage>ftv079</fpage>. <pub-id pub-id-type="doi">10.1093/femspd/ftv079</pub-id>.<pub-id pub-id-type="pmid">26416077</pub-id></mixed-citation>
              </ref>
              <ref id="B76">
                <label>76</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stainer</surname><given-names>DW</given-names></string-name>, <string-name><surname>Scholte</surname><given-names>MJ</given-names></string-name></person-group>. <year>1970</year>. <article-title>A simple chemically defined medium for the production of phase I <italic toggle="yes">Bordetella pertussis</italic></article-title>. <source>J Gen Microbiol</source><volume>63</volume>:<fpage>211</fpage>–<lpage>220</lpage>. <pub-id pub-id-type="doi">10.1099/00221287-63-2-211</pub-id>.<pub-id pub-id-type="pmid">4324651</pub-id></mixed-citation>
              </ref>
              <ref id="B77">
                <label>77</label>
                <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Lomask</surname><given-names>J</given-names></string-name>, <string-name><surname>Larson</surname><given-names>R</given-names></string-name></person-group>. Cough/sneeze analyzer and method. <year>2006</year>. <article-title>US patent USOO7104962B2</article-title>. <comment>US patent 7,104,962 B2. Application granted, 12 September 2006</comment>.</mixed-citation>
              </ref>
              <ref id="B78">
                <label>78</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barnett-Vanes</surname><given-names>A</given-names></string-name>, <string-name><surname>Sharrock</surname><given-names>A</given-names></string-name>, <string-name><surname>Birrell</surname><given-names>MA</given-names></string-name>, <string-name><surname>Rankin</surname><given-names>S</given-names></string-name></person-group>. <year>2016</year>. <article-title>A single 9-colour flow cytometric method to characterize major leukocyte populations in the rat: validation in a model of LPS-induced pulmonary inflammation</article-title>. PLoS One <volume>11</volume>:<elocation-id>e0142520</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0142520.</pub-id>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
